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Chapter I 
 
The Niemann-Pick type C disease 
 
1.1. Historical background and definition  
  
The first case of an individual affected by the then unknow Niemann-
Pick disease has been described by the German pediatrician Albert 
Niemann in 1914. Niemann described a child that died at 18 months and 
had an abnormal enlargement of liver and spleen, swelling and darkening 
facial skin and several alterations of nervous system (Niemann, 1914).  
Later on, in 1927, the German pathologist Ludwig Pick studied 
post-mortem tissues of several children who had similar symptoms 
(Pick, 1927). From their pioneering work was coined 
the eponym Niemann-Pick disease.  
For many years, this eponym was used to define a heterogeneous 
group of lipid storage diseases, with the common characteristic of 
hepatosplenomegaly and sphingomyelin accumulation in the 
reticuloendothelial and parenchymal tissues, with or not neurological 
involvement (Vanier, 2010).  
In 1958, Crocker and Farber discovered that the disease had a variable age of 
onset, clinical manifestations and sphingomyelin accumulation levels in tissues (Crocker and 
Faber, 1958). This led the researchers to classify Niemann-Pick disease into four subgroups 
(types A, B, C and D), each characterized by specific pathological features (Crocker, 1961).  
 
 
 
 
Albert Niemann 
(1880-1920) 
Ludwin Pick 
(1868-1944) 
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In particular: 
- the Type A is landmarked by a severe and early deterioration of the central nervous 
system (CNS) and a massive accumulation of sphingomyelin in bowels and brain;  
- the Type B shows a chronic course with a marked involvement of bowels in spite of a 
small involvement of CNS; 
- the Type C and the Type D are characterized by a sub-acute involvement of CNS, a 
slower progression of the disease and a more moderate and mild visceral accumulation. 
Noteworthy, Type D patients share a common geographical origin, Nova Scotia. 
 
In 1966, the research group lead by Brady demonstrated that type A (NP-A) and 
type B (NP-B) are very different from type C (NP-C) and -D, the first two types being 
characterized by a specific severe deficiency in lysosomal sphingomyelinase activity (Brady 
et al., 1966).  
Further investigations indicated that the prominent feature of NP-C and -D disease was an 
impairment in the intracellular trafficking of cholesterol and other lipids (Pentchev et al., 
1984).  
In 1997, it was discovered that most of NP-C patients had a common genetic trait: 
a mutation in the gene, later termed NPC1, located on chromosome 18q11 (Loftus et al., 
1997; Carstea et al., 1997).  
Three years later, it was found that a small proportion of patients who showed the 
characteristic symptoms of NP-C disease but had no mutations in the NPC1 gene, had a 
mutation in HE1 gene, subsequently renamed NPC2, located on chromosome 14q23.3 
(Naureckiene et al., 2000).  
These discoveries led to the distinction of two groups of Niemann-Pick disease: acid 
sphingomyelinase deficiencies (due to SMPD1 mutations, including types A, B and 
intermediate forms) and alterations in trafficking of endocytosed cholesterol in Niemann-Pick 
type C disease (due to NPC1 or NPC2 mutations). Type D is a distinct entity is no longer 
considered (Vanier, 2010). 
In summary, Niemann-Pick type C disease is an inherited lysosomal storage 
disorder, with autosomal recessive transmission, ultimately fatal and presenting variable 
neurovisceral symptoms, age of onset and life span (Pentchev et al., 1984; Vanier, 2010). It 
is caused by mutation of the genes NPC1 (~95% of cases) or NPC2 (~5% of cases), 
encoding for two proteins that cooperatively mediate the egress from endosomes/lysosomes 
of exogenous cholesterol (Vance, 2006; Peake and Vance, 2010).  
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The reduced functionality of these proteins causes an accumulation of cholesterol and other 
lipids such as sphingosine and gangliosides (GM2 and GM3) in late endosomal/lysosomal 
compartments (Pentchev and Tagle, 1996; Peake and Vance, 2010). This impairment leads 
to hepatosplenomegaly and progressive neurodegeneration that causes premature death 
(Peake and Vance, 2010).  
 Although NPC1 and NPC2 complementation groups are indistinguishable from a 
biochemical and clinical point of view, in literature is usually referred to them as NP-C1 and 
NP-C2 disease (Vanier et al., 2016).  
  
1.2. Epidemiology 
It is very difficult to estimate the real incidence and prevalence of the NP-C disease due 
to poor clinical knowledge of the disease combined with the relative difficulty in conducting 
appropriate biochemical tests (Vanier, 2010). The most recent incidence estimated 
worldwide is 1.12 affected patients per 100.000 live births (lb) (Wassif et al., 2016).  
However, in Portugal 9 cases were reported between 1985 and 2003 (prevalence 2.20 
per 100.00 lb) (Pinto et al., 2004). Prevalence estimates vary between 0.66 and 0.83 per 
100.00 lb in France, England and Germany on the basis of the diagnoses made between 
1988 and 2002 (Patterson et al., 2001; Vanier and Millat, 2003). In Australia were reported 
only 20 cases between 1980 and 1996 (prevalence 0.47 per 100.000 lb) and in Low 
Countries only 25 cases during the period 1970-1996 (prevalence 0.35 per 100.000 lb) 
(Meikle et al., 1999; Pinto et al., 2004).  
The low prevalence observed in Australia and Low Countries could be explained by 
misdiagnosis; the broad clinical spectrum of NP-C disease wasn’t recognized until the 90s 
of the last century and up to the mid-80s specific laboratory tests weren’t available (Vanier, 
2010).   
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1.3. Clinical manifestations 
 
The NP-C disease is a neurovisceral condition that clinically manifests with systemic, 
neurological and psychiatric symptoms and cognitive impairment. Since the disease 
has different clinical features depending on the age of onset, some authors have proposed 
5 different subgroup classification (Wraith et al., 2009) (Figure 1): 
- Pre-peri natal (before 3 months of age); 
- Early infantile (between 3 and 12 months of age); 
- Late infantile (between 2 and 6 years of age); 
- Juvenile (between 6 and 15 years of age); 
- Adolescent/Adult (after 15 years of age).  
 
 
Figure 1. Schematic representation of clinical manifestations of NP-C disease 
(Vanier, 2015).  
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1.3.1. Systemic symptoms  
Systemic symptoms of NP-C disease mainly include hepatosplenomegaly, an 
abnormal simultaneous increase of spleen (splenomegaly) and liver (hepatomegaly) 
volumes, and associated symptoms. Pulmonary infiltration with foam cells are usually 
present only in early onset forms and in subjects with mutation in NPC2 gene (Griese et al., 
2010; Bjurulf et al., 2008). Usually, in late onset forms, hepatosplenomegaly is asymptomatic 
and often is not clinically recognized. Data suggest that it occurs in the 85% of patients 
(Vanier, 2010), whereas isolated hepatomegaly is less common in adults (Sèvin et al., 2007).  
Often, patients with severe pre-/peri-natal onset have a history of neonatal jaundice 
(Iturriaga et al., 2006; Imrie et al., 2007) and can manifest other systemic symptoms (Vanier, 
2010; Garver et al., 2007; Spiegel et al., 1999; Sedel et al., 2008) such as an abnormal 
storage of fluid in fetal compartments (fetal hydrops) and/or in peritoneal cavity (ascites), 
accumulations of bile components in bloodstream (neonatal cholestasis) and hepatic 
failure.   
However, when systemic symptoms occur, they always precede the onset of 
neurological signs that may also start after several years (Vanier, 2010) (Figure 1). 
 
1.3.2. Neurological symptoms 
The neurological manifestations occur along a continuous spectrum and there is a 
considerable overlap between the various forms regardless the age of onset. Often, the 
onset of neurological manifestation is insidious, with subtle signs such as the presence of a 
low muscle tone (central hypotonia) or frequent falling.  
The prominent neurological hallmark of NP-C disease is identifiable in oculomotor 
abnormalities that are present in the 81% of subjects and usually emerge in late childhood 
with a reduction of saccadic eye movements (Garver et al., 2007). Initially, the ocular 
disturbance affects vertical saccadic movement and subsequently also the horizontal ones, 
reflecting the progressive degeneration of the brain stem (Abel et al., 2009; Solomon et al., 
2005). Over the time these abnormalities may progress and cause vertical supranuclear 
gaze palsy (VSGP) that begins with a gradual reduction of the speed of saccadic movement 
(while the saccadic latency remains normal) and leads to a saccadic palsy (Solomon et al., 
2005; Lengyel et al., 1999). The vestibulo-ocular reflex appears normal until the terminal 
stage of degeneration.  
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In the early infantile onset cases, there is a delay in the developmental milestones. 
These include speech, oculo-motor and social delay and in particular motor delay such 
as slow movements, clumsiness and poor head control (Mengel et al., 2013). Most of these 
children fail to reach some developmental milestones in the following order: delay in grasping 
and moving object, lack of visual attention, falls and tendency to cling parents and objects 
to maintain balance (Mengel et al., 2013). Often, they never learn to walk. During disease 
progression there is a loss of poorly acquired motor skills followed by spasticity and death 
within 5 years of age (Vanier, 2010). 
In the forms with late onset, several striatum signs appear, such as dystonia and 
cerebellar signs, such as cerebellar ataxia, dysarthria and dysphagia (Sarna et al., 2003; 
Walkley and Suzuki, 2004) (Figure 1).   
Dystonia consists in an abnormal involuntary muscular contraction, causing 
inappropriate and repetitive tremulous and twisting movements, which can affect hands and 
face or influencing posture (Sedel et al., 2008; Albanese et al., 2013). A typical dystonic sign 
that occurs in NP-C patients is a forced smile during speaking (Mengel et al., 2013). In the 
terminal stage of the disease, dystonia may also involve trunk and neck (Sedel et al., 2008).   
Cerebellar ataxia is the lack of coordination of voluntary movement associated with the 
loss of cerebellar Purkinje cells (PC) (Sarna et al., 2003; Mengel et al., 2013). It occurs in 
the 76% of cases with adolescent/adult onset (Sèvin et al., 2007). NP-C subjects manifest a 
“slow” ataxia characterized by slow movements compared to other ataxic patients. Children 
suffering from a mild form of the disease may appear slower than healthy ones. For example, 
they walk instead of running and grab objects cautiously. Usually, ataxia appears after 
dystonia. Since ataxia may have different etiologies, if it is the only neurological 
manifestation, it’s better to wait the onset of additional symptoms prior to suspect that the 
patient is affected by NP-C disease (Mengel et al., 2013).  
Dysarthria is a motor speech disorder characterized by a poor articulation of phonemes 
due to a loss of control of the motor-speech system. It occurs in the 63% of cases with 
adolescent/adult onset and results from the combination of ataxia and dystonia (Sèvin et al., 
2007).  
Dysphagia, consisting in difficulty swallowing, begins to manifest with coughing or 
chocking during feeding. It can occur early in the course of the disease and represents a 
serious problem in the clinical management and a risk factor for mortality because it may 
result in the interruption of feeding and in fluid or food aspiration (Chien et al., 2007; 
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Fecarotta et al., 2011). It occurs in the 37% of cases with adolescent/adult onset (Sèvin et 
al, 2007). 
Other less common symptoms include cataplexy, seizures, sensorineural hearing 
loss and peripheral neuropathy (Yanjanin et al., 2010; Zafeiriou et al., 2003). 
Cataplexy is a relatively specific and common sign of NP-C disease (Garver et al., 
2007). It’s manifested by the loss of muscular tone of legs and sometimes of neck and jaw, 
in response to emotions that produce laughter (gelastic cataplexy). This symptom is often 
overlooked, erroneously as the consequence of ataxia or seizures (Vanier, 2010). It occurs 
in half of the patients with late infantile and juvenile onset and in the 16% of the cases with 
adolescent/adult onset (Sèvin et al, 2007). 
However, seizures occur mostly in late infantile and juvenile forms and only in 4% of 
cases with adolescent/adult onset (Sèvin et al., 2007). They can be both partial and 
generalized, myoclonic, tonic-clonic and absence (Mengel et al., 2013).  
Sensoriniural hearing loss is the loss of hearing or deafness caused by inner ear, 
sensory organ or vestibule-cochlear nerve disorders. It affects the 20% of patients and can 
be light or severe (Vanier, 2010). Because proper cholesterol trafficking is crucial in auditory 
physiology (Ward et al., 2010; Crumling et al., 2012), this symptom is strictly associated to 
NP-C disease. 
Lastly, peripheral neuropathy is a rare complication of NP-C disease; some patients 
have a reduced nerve conduction velocity due to a mild demyelination (Zafeiriou et al., 2003).  
 
1.3.3. Psychiatric manifestations 
 Psychiatric manifestations often occur in patients with adolescent/adult onset 
of NPC (Vanier, 2010; Imrie et al., 2007; Sèvin et al., 2007). However, juvenile onset cases 
with a history of behavioral problems may develop psychiatric disorders during adolescence 
(Turpin et al., 2003; Sandu et al., 2009).  
 The most prominent behavioral problems of juvenile onset cases are Attention 
Deficit Hyperactivity Disorder (ADHD), learning impairment, deficit in expressive 
language, aggression and self-mutilation. In the 25% of cases with late onset is present 
a schizophrenia-like psychosis, which manifests with visual and/or auditory hallucinations, 
disorganized thinking and behavioral impairment (Vanier et al., 1991; Walterfang et al., 
2009).  
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 Other psychiatric disabilities reported in the literature are major depression, 
bipolar disorder and obsessive-compulsive disorder (Zafeiriou et al., 2003; 
Trendelenburg et al., 2006).  
 
1.3.4. Cognitive impairment and neuropsychological profile 
 
 The impairment of cognitive functions is observed in all patients with 
adolescent/adult onset (Imrie et al., 2002; Sèvin et al., 2007) and is less commonly 
recognized in early childhood forms of the disease.  
 However, patients with late infantile and juvenile onset may be display poor 
school performance, learning impairment and intellectual disability (Imrie et al., 2007).  
Cognitive dysfunction in NP-C disease usually begins with fronto-subcortical deficits 
characterized by deficits in executive functions, reduced processing of language and 
verbal working memory deficits (Sèvin et al., 2007; Klarner et al., 2007). With the 
progression of the disease, patients experience a more general cognitive decline, leading in 
many cases to dementia with prominent dysexecutive syndrome and verbal memory 
disorders in spite of normal visuospatial memory skills (Hulette et al., 1992).  
The dysexecutive syndrome is characterized by inhibition deficits, planning and 
organization, diminished comprehension and cognitive flexibility (Klarner et al., 2007). 
The analysis of clinical history of patients revealed the presence of some typical 
neuropsychological abnormalities, including: 
- deterioration of fine and gross motor skills, with indistinct articulation; 
- alterations of logical and abstract thinking, difficulty in complex associations and 
divided attention; 
- difficulty concentrating and limited memory (specially working memory); 
- lack of distance (often interpreted as a sexually uninhibited behavior); 
- deficit in word retrieval, followed by the use of stereotyped expression; 
- the ability to perform activities of daily living like bathing, dressing autonomously 
with gradual loss of personal hygiene. 
 
Some authors have proposed a classification system in 5 phases to categorize the severity 
of the NP-C disease (Higgins et al., 1992): 
 Phase 0. The disease is diagnosed by biochemical, histological, genetic and 
molecular examination but patients don’t manifest typical symptoms of the disease, yet; 
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 Phase I. The initial symptoms such as minor disorders of movement and cognitive 
difficulties are present, but sometimes there are recognized only after a painstaking 
observation because patients can appear normal. Sometimes the gait can be unstable, a 
mild ataxia or dystonia can be present, horizontal saccadic eye movements can be slow, 
vertical supranuclear gaze palsy can be limited in moving down or up and the language may 
be slowed; 
 Phase II. The severity of motor and cognitive deficit continues to increase. The 
gait is increasingly unstable; balance problems are present even though the patient is still 
able to walk independently for short distances (100 m). Ataxia, dystonia, vertical 
supranuclear gaze palsy and dysarthria become increasingly serious. The speech, although 
preserved is poor (reduced sentences to simple grammatical structures and vocabulary with 
depleted) and is landmarked by articulation difficulties.   
 Phase III. Significant cognitive and motor dysfunction requiring nursing care. The 
patient can walk independently only if supported and for a few meters; needs assistance 
with eating, dressing, bathing and becomes incontinent. The speech becomes very limited 
and reduced to 1/2-word phrases; 
 Phase IV. Neurological deficits severely compromise walking abilities or 
determine a vegetative state. The patient is unable to speak or articulate clearly. 
 
1.4. Genetics of NP-C disease 
 
 Linkage studies identified two complementation groups of NP-C disease 
(Steinberg et al., 1994; Vanier et al., 1996), The NPC1 one, which is responsible of ~95% of 
cases (Millat et al., 1999; Carstea et al.,1994) and the NPC2, which is responsible for the 
remaining ~5% of cases (Millat et al., 1999).  
 
1.4.1. Structure of NPC1 protein  
 
 The NPC1 gene includes 25 exons, spanning ~56 Kb region and is located on 
chromosome 18 in position 11.2 (Vanier and Millat, 2003).  
This gene encodes for the endolysosomal NPC1 glycoprotein having a theoretical molecular 
weight of ~180 kDa and consisting of 1278 amino acids (aa) forming 13 transmembrane 
domains. Behind its transcription, NPC1 protein is synthesized and N-glycosylated in the 
endoplasmic reticulum (ER). Subsequently it is transported to the Golgi cisternae, where the 
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oligosaccharide moieties are further modified. Then, the mature NPC1 form reaches the late 
endosome/lysosome compartments (Watari et al., 1999).  
 The NPC1 protein is provided with signal sequence (aa 1-24), a N-terminal 
domain between aa 25-264 (luminal loop-1; LL-1) that binds cholesterol and two large 
loops (LL-2; LL-3) located in the vesicle lumen. LL2 (aa 371-615) corresponds to the binding 
domain for NPC2 protein and Ebola virus (Lu et al., 2015). LL3 is a cysteine-rich loop (aa 
855-1098) containing the ring finger motif that mediates protein-protein interactions. 
Between these two luminal loops (aa 616-791) there is a putative sterol-sensing domains 
(SSD). The C-terminal is rich in leucine residues protruding into the cytoplasm and 
necessary for the proper functioning of protein in the endocytic pathway (lysosomal 
targeting motif; LLNF) (Watari et al., 1999; Davies et al., 2000) (Figure 2). 
 The sterol sensing domain shares a 30% identity with the sterol-sensitive domain 
of 3-hydroxy-3-methyglutaryl-coenzyme A reductase (HMGR) enzyme, the cutting-activating 
protein (SCAP) and the Sonic Hedgehog receptor patched (Davies et al., 2000). 
 
 
 
Figure 2. Schematic representation of NPC1 protein structure (Lu et al., 2015). 
 
 
 
1.4.2. Structure of NPC2 protein   
 
 The NPC2 gene includes 5 exons spanning a ~13.5 Kb region and is located on 
chromosome 14 in position 24.3 (Vanier and Millat, 2003). This gene encodes for a small 
soluble 132 aa glycoprotein, formerly He1, having a predicted molecular weight of ~18 kDa 
(Vanier et al and Millat, 2004; Lu et al., 2015). 
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 The NPC2 protein contains a proline-rich region (PVPFPIP), six cysteine residues 
and 1 to 3 glycosylation sites (Larsen et al., 1997; Friedland et al., 2003; Vanier and Millat, 
2004).  
 The 3D structure of the bovine protein shares an 80% sequence identify with the 
human protein and is provided with 7 h-strands arranged in 2 h-sheet stabilized by 3 disulfide 
bonds, conferring to the protein an immunoglobulin-like -sandwich fold (Friedland et al., 
2003). NPC2 protein is characterized by several cholesterol-binding sites (Figure 3).  
 
  
Figure 3. Secondary structure of the bovine NPC2 protein. The cholesterol-binding 
cavity are reported in light blue (Adapted from Ioannou and Yiannis, 2005).  
 
 
1.4.3. NPC1 and NPC2 gene mutations  
 
 Currently, 380 and 22 distinct mutations in NPC1 and NPC2 genes, respectively, 
(Runz et al., 2008; Stenson et al., 2009; Vanier et al., 2016) are recorded in mutation 
database.  Most of these mutations are missense (71%) and nonsense, although genomic 
deletions and intronic mutations have been also reported (Bauer et al., 2002; Millat et al., 
2005; Runz et al., 2008; Macias-Vidal et al., 2011).  
The mutations in NPC1 gene can be localized and negatively affect all functional 
domains except the leucine zipper motif. More than a third of the mutations occur in the 
cysteine rich luminal loop, mostly in the region between aa 927-958 (Vanier and Millat, 
2003), the most frequent ones are: I1061T, P1007A and G992W (Figure 4).  
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Figure 4. Topology of the most common NPC1 mutations (Vanier and Millat, 2003).  
 
The I1061T mutation occurs mainly in Western European descent patients (20% of 
France-UK and 15% of USA patients) and is very common in patients from the Spanish-
American isolate, southern Colorado and New Mexico (Klünemann et al., 2002; Vanier and 
Millat, 2003).  
The P10071A mutation is the second most common mutation in European patients, 
while the G992W one is typically found only in Nova Scotia patients (Greer et al., 1999; 
Yamamoto et al., 2000; Sun et al., 2001; Meiner et al., 2001; Millat et al., 2001a; Bauer et 
al., 2002; Tarugi et al., 2002; Vanier and Millat, 2003).  
In Japanese patients is very prevalent the R518Q mutation, while in Italian patients 
the P474L (Tarugi et al., 2002; Yamamoto et al., 2000). Other common missense mutations 
are: R404Q, Y852C, D874V, S940L, D948N, S954L, R978C, M1142T, N1156S, and 
R1186H (see Table 1, for details).  
While missense mutations of NPC1 gene are associated to more severe and late 
onset disease forms, nonsense mutations are typical of infantile onset disease forms, which 
also display particularly severe neurological impairment (Millat et al., 2001a). 
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Table 1. Missense mutation of NPC1 gene (Scott and  Ioannou, 2004).  
 
 At least 30 families have been identified worldwide with mutations in the NPC2 
gene. In most cases, the mutation generates a truncated protein due to a premature stop 
codon (Vanier and Millat, 2004). In a first study, the prevalence of E20X nonsense mutation, 
which is associated with infantile onset and a very severe clinical phenotype, was estimated 
at 50%, but more recent investigations have made it to come down to 30% (Millat et al., 
2001a; Vanier and Millat, 2004). Missense mutations are associated with more variable 
phenotypes and age of onset (Millatt et al., 2001a; Park et al., 2003; Chikh et al., 2005); 
V39M is associated with the adult onset of neurological features and a slow progression of 
disease, while the C99R causes a very severe neonatal/infantile disease (Vanier and Millat, 
2004). Figure 5 shows the most common NPC2 mutations.  
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Figure 5. Schematic representation of NPC2 gene (upper) and NPC2 protein (lower), 
showing the localization of NPC2 mutations (Adapted from Vanier and Millat, 2004).  
 
 
1.4.4. NPC1 and NPC2 function: a key role in the intracellular trafficking of 
lipids  
 
It has been shown that NPC1 and NPC2 proteins cooperatively mediate the egress 
from endosomes/lysosomes of exogenous cholesterol brought to the cells by the low-density 
lipoprotein (LDL) (Peake and Vance, 2010).  
Cholesterol (C27H45OH) is a polycyclic aliphatic alcohol, belonging to the family of 
sterols. Usually in cells it is present as unesterified, or free, cholesterol (an amphipathic 
molecule with the polar hydroxyl group in position 3 and the remaining part of the molecule 
apolar). However, it can also be present as esterified cholesterol, or cholesterol ester, in 
which the hydroxyl group is bound to a carboxylic acid, giving rise to a completely apolar 
molecule (Figure 6). 
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Figure 6. Chemical structure of cholesterol and cholesterol esters. The cholesterol 
consists of three regions: a hydrocarbon tail, a ring structure region with 4 hydrocarbon rings and a 
hydroxyl group. The enzyme Acyl-CoA cholesterol acyltransferase (ACAT) catalyzes the condensation 
reaction between cholesterol and a fatty acid leading to the formation of an ester bound between the 
carboxyl group of the fatty acid and the hydroxyl group in position 3 of cholesterol.  
 
 
The brain is the most cholesterol-rich organ of the human body: about 25% of whole-body 
cholesterol is localized in the brain while the brain represents only the ~2% of body mass 
(Vance, 2006). 
Within the brain cholesterol performs important functions relating to cells 
architecture and structure. In fact, it is involved in neuronal development, synapses formation 
and transmission, maintenance of synaptic plasticity, neurite growth, transport of synaptic 
vesicles and release of neurotransmitters. It is also an essential component of the plasma 
membrane (PM) and is involved in the formation and maintenance of lipid rafts defined as 
small and high dynamic domains (10-200 nm), rich in sterols and sphingolipids that 
compartmentalize cellular processes. In the cytoplasm, cholesterol is the precursor for the 
synthesis of bile acids, steroid hormones, oxysterols, myelin and Vitamin D (Miller and 
Strauss, 1999; Kosters et al., 2003; Ikonen, 2006). Because of these pleiotropic functions, 
an imbalance in the homeostasis of cholesterol severely affects proper brain functioning.  
All cells are provided with the biochemical machinery needed for cholesterol 
synthesis starting from acetyl CoA, although cholesterol synthesis is prominent in liver cells.   
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Cholesterol does not cross the blood-brain barrier once it is fully established after 
birth (Abbott et al., 2010) making the adult brain mostly dependent on endogenously-derived 
cholesterol. Accordingly, cholesterol de novo synthesis occurs in neurons, astrocytes and 
oligodendrocytes during early postnatal neurogenesis, thereafter becoming most prominent 
in astrocytes that provide it to neurons (Benarroch, 2008).  
In astrocytes, cholesterol is synthesized by the HMGR enzyme, which is regulated 
by a negative feedback mechanism through the sterol-regulated element binding protein 
(SREBP) that binds to the sterol -regulated element- 1 (SRE-1) in the promoter of the HMGR 
gene. Then, cholesterol is complexed with Apoliprotein E (APOE), the largest apoliporotein 
expressed in the central nervous system, and is secreted via adenosine triphosphate (ATP) 
binding cassette (ABC) transporter family member A1 (ABCA1), also known as cholesterol 
efflux regulatory protein (CERP) (Beffert et al., 1998; Karten et al., 2000). The APOE-
cholesterol complex is then uptaken by neurons via binding low density lipoprotein receptor 
(LDLR), and once released in late exosomes/lysosomes compartments (LE/L) the 
cholesterol is de-esterified by the action of lysosomal acid lipase enzyme (LAL) (Herz, 2009) 
(Figure 7). 
 
 
Figure 7. Cholesterol metabolism in mature Central Nervous System (CNS) (Fiorenza et 
al., 2013).  
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As already pointed out, NPC1 and NPC2 proteins mediate the egress of cholesterol 
from endosomes/lysosomes by ways not fully characterized yet. Two possible mechanisms 
regarding the sequential action of these two proteins have been proposed (Infante et al., 
2008) (Figure 8). According to the first model (Model A), cholesterol stored in vesicles binds 
to the NPC2 protein localizing in the lumen of LE/E. Subsequently, NPC1 receives 
cholesterol from NPC2 and transfers it across membranes delimitating LE/E, making 
cholesterol available to others cellular compartment, including the ER, PM and mitochondria 
(Vance, 2006; Wang et al., 2010). The second model (Model B) predicts that NPC1 removes 
cholesterol from LE/E vesicles and releases it to NPC2 localizing on the membrane surface 
of LE/E. Both models predict the participation of an additional protein, not yet identified, 
which transport cholesterol from LE/E membrane to other sites (Karten et al., 2000).  
 
 
 
Figure 8. Models for the efflux of cholesterol from LE/E compartment (Infante et al., 
2008).  
 
In ER cholesterol is re-esterified by the action of cholesterol acyltransferase (ACAT) 
and stored as cholesteryl ester; alternatively, it is released by neurons through APOA1-
ABCA1 complex or included in lipid rafts. In mitochondria cholesterol is hydrolyzed to 24-
hydroxy cholesterol (24-OHC) by the cytochrome P450 (CYP) family member (CYP46), and 
therefore it can freely cross the blood brain barrier or be released into the plasma. Moreover, 
when 24-OHC is internalized by astrocytes or neurons it binds the liver X-activated receptors 
(LXRs), important member of the nuclear receptor that regulates cholesterol homeostasis, 
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enters in the nucleus to induce the expression of the gene that regulates LXR, APOE and 
ABCA1 (see Figure 7) (Fiorenza et al., 2013).  
Besides that, NPC1 protein plays a key role in the LE/L efflux of sphingosine and-
tochopherol, as well as in the retrograde trafficking of GM2 and GM3 gangliosides (Lloyd-
Evans et al., 2008; Zhou et al., 2011; Yèvenes et al., 2012).  
 
1.4.5. Consequence of NPC1 and NPC2 mutations on lipids trafficking  
 
Although in NP-C disease the endocytic uptake of LDL-cholesterol and the 
hydrolysis of LDL-derived cholesteryl esters to unesterified cholesterol in LE/E are normal, 
the egress of unesterified cholesterol from LE/L is impaired (Sokol et al., 1988; Liscum, 2000; 
Neufeld et al., 1996). This causes an accumulation of cholesterol, sphingolipids (sphingosine 
and sphingomyelin), glycolipids (glucosylceramide, lactosylceramide, gangliosides GM2 and 
GM3), and other lipids such as bis(monoacylglycerol)phosphate (BMP) and lysosome-
specific phospholipid (LBPA) in LE/L (Watanabe et al., 1998; Kobayashi et al., 1999; Liscum 
and Munn, 1999; Zervas et al., 2001b; te Vruchte et al., 2004).  
Therefore NP-C disease is mainly conceived as a cholesterol storage disease, 
although it is still unclear why the defective function of NPC1/NPC2 proteins causes the 
accumulation of other lipids. In this respect, several studies indicate that cholesterol could 
not be the primary toxic metabolites of NP-C disease (Davies et al., 2000; Sun et al., 2001; 
Infante et al., 2008).  
In 2008, Lloyd-Evans et al., proposed that NP-C disease is a sphingosine storage 
disease. Sphingosine, with chemical formula CH3-(CH2)12-CH=CH-(CHOH)-(CHNH2)-
CH2OH), is an 18-carbon amino alcohol with an unsaturated hydrocarbon chain, that form 
the primary part of sphingolipids (Figure 9).  
 
 
           
Figure 9. Chemical structure of sphingosine  
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The sphingosine efflux from LE/L is a key step in the salvage pathway of GSL 
biosynthesis and promotes the sphisongosine-1-phosphate (S1P) protein synthesis, which 
in turns regulates the transcription of several enzymes implicated in the biosynthesis of 
cholesterol (Tettamanti et al., 2003; Ozbay et al., 2004).             
After the inactivation of NPC1 protein, the first event observed is the accumulation 
of sphingosine in lysosomes and the concomitant reduction of sphingosine efflux from 
lysosomes. Subsequently, sphingosine storage causes an impairment of calcium 
homeostasis, indicated by the low calcium levels measured in acidic compartments, that 
may cause defective endocytosis (Lloyd-Evans et al., 2008) (Figure 10). The sphingosine 
storage may also explain the accumulation of sphingomyelin and glycolipids (GLS), as they 
have all a sphingosine backbone (Erickson, 2013).  
 
 
 
 
Figure 10. Proposed pathological cascade in NPC1-cells (Platt et al., 2016).  
 
In addition, it was also reported that -tochopherol (Figure 11, a naturally-
occurring form of vitamin E with potent antioxidant properties) accumulates in LE/L (Yèvenes 
et al., 2012). 
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Figure 11. Chemical structure of -tochopherol (α-TOH), consisting of 2 benzene rings 
bound to a hydrocarbon chain. 
 
The intracellular trafficking of α-TOH requires the activity of several proteins that 
also participate in the cholesterol trafficking pathways, such as NPC1L1 protein, which has 
extensive homology with NPC1 (Siato et al., 1993; Davies et al., 2000; Reboul et al., 2006; 
Reboul et al., 2009).  
The intracellular accumulation of α-TOH in LE/L of NPC1-deficient cells (Yèvenes et 
al., 2012), emphasizes the role of NPC1 in its intracellular trafficking, also suggesting a block 
of endocytosis, which in turn would hinder the antioxidant functions of α-TOH in other cellular 
compartments.  
 
1.5. Murine models of NP-C1 disease  
 
 Several animal models, including feline (Lowenthal et al., 1990), canine 
(Kuwamura et al., 1993) and murine (Penthcev et al., 1984; Maue et al., 2012), have been 
developed during the last three decades.  
 One of the first murine model of NP-C1 disease, known as Npc1spm, was 
developed in 1982 by Miyawaki on C57BL/KsJ strain mice (Miyawaki et al., 1982). It was 
generated by inserting a 43 base pair (bp) following codon 971, thus generating a frame shift 
mutation and a premature termination codon within the LL1 domain of the protein, which 
contains the cholesterol binding site.  
 Concomitantly, Pentchev and coll. characterized the knock out model of NP-C1 
disease, known as Npc1nih, on BALB/C strain mice, that has become the most widely used 
model (Pentchev et al., 1984). This mouse line originated from a spontaneous mutation due 
to a retrosposon insertion of 1100 bp of DNA, causing a frame shit that almost completely 
abrogated the Npc1 gene (Loftus et al., 1997). Western blot analysis (WB) revealed the total 
absence of Npc11 protein in these mice, indicating the complete loss of function and making 
this model a true “knock out” (Maue et al., 2012).  
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 In 2012, a novel mouse model commonly referred to as Npc1nmf164 was generated 
and phenotypically characterized at the Jackson Laboratory (Maue et al., 2012). This mouse 
model was generated by N-ethyl-N-nitrosourea (ENU) mutagenesis of C57BL/6J strain mice 
and later transferred to BALB/c mouse strain. Npc1nmf164 mice carry a point mutation in the 
Npc1 gene, consisting in a single nucleotide substitution (A to G in the cDNA 3163 bp) that 
leads to a change from aspartate (coded by GAT codon) to glycine (coded by GGT codon) 
in position 1005 (D100G) of the protein. This change occurs in the cysteine-rich luminal loop 
of the NPC1 protein, where about one-third of human mutations identified up to now are 
located (Vanier, 2010; Maue et al., 2012). Although quantitative real-time polymerase chain 
reaction (qRT-PCR) revealed a slight reduction of Npc1 mRNA level (a roughly 20% 
reduction), WB analysis showed a significant reduction of protein level (Maue et al., 2012).   
Histological analysis of liver, spleen and brain revealed that the abnormal accumulation of 
cholesterol and the loss of Purkinje cells proceeded at a slower rate in Npc1nmf164 compared 
to Npc1nih mice. Therefore, while Npc1nih model mimics severe and early onset forms of the 
disease, the Npc1nmf164 model mimics the late-onset and slower progressive forms of NP-C1 
disease, which include most of the human cases (Maue et al., 2012). 
 
1.6. Diagnosis  
 
As already pointed out, the clinical presentation of NP-C disease is extremely 
heterogeneous and is characterized by a wide range of symptoms, whose progression 
depends on the age of onset (Patterson et al., 2001; Imrie et al., 2007; Vanier, 2010). This 
hampers the possibility to achieve an early diagnosis and often causes misdiagnosis. For 
this reasons the diagnosis of NP-C disease can require a very long time (years) and the 
intervention of specialists in different disciplines (Vanier, 1997; Patterson et al., 2001; Wraith 
et al.,2009).   
In addition, the rarity of the NP-C disease and the lack of clear guidelines on therapeutic 
monitoring, represent significant challenges in the clinical management of the disease. In 
most countries the NP-C disease is managed in non-specialist centres.  
Initial screening assessment of patients is aimed at distinguishing the disease from 
other lysosomal storage disorders and represents a prerequisite for a careful evaluation of 
the onset and evolution of symptoms and signs over the time (Wraith et al., 2009; Vanier, 
2010).  
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 In 2009, Wraith and coll. proposed an ideally series of analyses to be carried in 
individuals possibly affected. These tests can be grouped into three micro-areas of 
investigation: reconstruction of medical history, clinical investigation and execution of 
laboratory tests.  
 The reconstruction of the patient's medical history includes the analysis of the 
first appearance of neurological manifestations, the presence of splenomegaly and neonatal 
cholestasis, as well as coordination, muscle tone and posture problems., It also considers if 
the patient had poor school performance or limited work ability and if he/she had episodes 
of cataplexy and/or seizures. 
 The clinical investigation includes at first a physical examination (vital signs, 
body weight, head circumference) and a comprehensive neurological examination with the 
aim of identifying the presence of characteristic signs and symptoms. The presence of NP-
C disease is easily inferred in patients that show the most typical symptoms of the pathology, 
such as the simultaneous presence of splenomegaly, ataxia, and VSGP (Vanier, 2010). 
From a neurological point of view, it is important to evaluate muscle tone, strength and motor 
reflexes by specific tests, along the assessment of movement (ataxia and dystonia) and 
swallowing tests (Wraith et al., 2009; Vanier, 2010). Because abnormal saccadic movement 
(SEM) is often among the first neurological symptoms of the disease, ophthalmological 
assessment is also particularly relevant. The clinical examination includes an ultrasound 
evaluation of liver and spleen size, psychometric assessment and a psychiatric evaluation.  
Sometimes patients are also subjected to hearing tests (audiogram and/or brainstem evoked 
potential) and nerve conduction analyses (electromyography) to assess the presence of 
peripheral neuropathy.  
 Given that routine laboratory tests often reveal no anomaly, Wraith and coll. 
(2009) proposed a specific laboratory algorithm (Figure 12).  
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Figure 12. Laboratory diagnosis algorithm (Vanier, 2010).  
 
 The ultimate diagnostic test to diagnose NP-C disease must be able to detect the 
presence of an impairment in the intracellular trafficking and homeostasis of cholesterol. Up 
to now, the Filipin test represents the most sensitive and specific assay for NP-C disease 
diagnosis (Vanier et al., 2016).  
 Filipin is an antifungal antibiotic forming specific complex with unesterified 
cholesterol that can be observed by fluorescence microscopic examination (Vanier, 2010). 
While in fibroblast cultures of NP-C patients nearly all cells are display fluorescent 
perinuclear vesicles, in normal subject only about the 10% of cells are filipin-positive (Vanier 
et al., 2016). Although the 85% of NP-C patients display the “classical” storage pattern, about 
the 15% of them shows a “moderate” profile with only a small number of positive cells and 
the remaining 5 % of cases is completely negative.  
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 In any case, the diagnosis requires the detection of mutations in NPC1 or NPC2 
genes (Millat et al., 2005; Wraith et al., 2009; Vanier, 2010; Vanier et al., 2016) by Sanger 
and next-generation sequencing (NGS) methods (Bounford and Gissen, 2014).  
 More recently a cholesterol esterification test, evaluating the cholesteryl ester 
formation and the re-esterification of cholesterol by ACAT that are particularly impaired in 
NP-C cells was developed (Pentchev et al., 1987; Vanier et al., 1991; Vanier, 2016). It is 
considered a useful test to be performed, in addition to the filipin test and prior the 
identification of possible mutations in the NPC1 or NPC2 genes (Vanier et al., 2016). 
However, both filipin and cholesterol esterification tests are invasive because require 
fibroblast isolation from skin biopsies.  
 In the last few years, many researchers have sought to identify specific 
biomarkers possibly allowing the diagnosis by blood or urinary tests, thus reducing time 
and costs (Vanier et al., 2016).  
 The first approach measures the plasma chitotriosidase activity that represents 
a valid biomarker of Gaucher disease and is typically increased in lysosomal storage 
diseases, including NP-A -B and -C, compared to normal subjects (Ries et al., 2006). 
However, an increase in plasma chitotriosidase activity level occurs in other and more 
common conditions such as stroke and type 2 diabetes mellitus. Moreover, in NP-C1 
patients with late onset its level can be normal (Bustamante et al., 2014; Elmonem et al., 
2016; Vanier et al., 2016).  
 A more recent approach proposed for diagnosis is the plasma oxysterol-based 
tests. Although there are many oxysterols, whose levels are increased in NP-C1 patients, 
cholestane-3β,5α,6β-triol (C-triol) and 7-ketocholesterol (7-KC), appeared of particular 
interest for diagnosis (Vanier et al., 2016). The blood plasma levels of these two metabolites 
are significantly increased in both Npc1-/- mice and NP-C1 patients (Zhang et al., 2008; 
Porter et al., 2010; Jiang et al., 2011; Pajares et al., 2015).   
Evidence suggests that C-triol has a greater discriminatory power than 7-KC (Porter et al., 
2010; Jiang et al., 2011; Pajares et al., 2015; Boenzi et al., 2014; Reunert et al., 2016). 
However, it has been shown that the levels of both metabolites are high in other pathological 
conditions such as Niemann-Pick disease type A (NP-A), Niemann-Pick disease type B (NP-
B), LAL deficiency and cerebrotentinus xanthomatosis (Klinke et al., 2015; Romanello et al., 
2016).  
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Another promising approach for the NPC diagnosis is the analysis of 
lysosphingolipids plasma levels. Lysosphingolipids are toxic metabolites which contribute 
to the pathophysiology of several diseases (Suzuki,1998; Sueyoshi et al., 2001). 
Globotriaosylsphingosine and glucosylsphingosine belong to this class of molecules and are 
great plasma biomarkers for Fabry disease and Gaucher disease, respectively (Aerts et al., 
2008; Dekker et al., 2011). 
Galactosylsphingosine and sphingosylphosphorylcholine (SPC; lysosphingomyelin) are 
suitable markers for the screening of NP-B and Krabbe disease (Chuang et al., 2013; 
Chuang et al., 2014). Preliminary studies have shown that SPC plasma levels are also 
increased in patients with NP-C disease (Welford et al., 2014; Kuchar et al., 2015; Piraud et 
al., 2015) and even more increased levels were found in patients suffering for NP-A and NP-
B (Raymond et al., 2015; Motta et al., 2016).  
An emerging approach is the analysis of bile acid metabolites that could replace 
the analysis of oxysterol in the near future (Vanier et al., 2016). The bile acid 3β-sulfooxy-
7β-N-acetylglucosaminyl-5-cholen-24-oic acid (SNAG-Δ5-CA) and its glycine-and taurine-
conjugates is particularly high in the urine of NP-C patients (Alvelius et al., 2001; Maekawa 
et al., 2013). In addition, other authors found an increase of two bile acid metabolites: 3β-
hydroxy-7β-N-acetylglucosaminyl-5-cholenoic acid and N-(3β,5α,6β-trihydroxycholan-24-
oyl) glycine (Jiang et al., 2016; Mazzacuva et al., 2016). 
Recently, it has been shown that an isoform of Bis(monoacylglycero)phosphate 
(BMP or LBPA) named di-22:6-BMP displays a 50-fold increase in the urine of NP-C patients 
(Liu et al., 2014). BMP is a phospholipid that plays a key role in both cholesterol processing 
and sphingolipids degradation in the LE/L (Vanier, 2015). Further studies are needed to 
prove its usefulness in the diagnosis of NP-C disease (Vanier et al., 2016).  
Cluzeau and coll. (2012) reported an increase in serum levels of two proteins: the pro-
infiammatory galectin-3 (LGALS3), and the lysosomal protease cathepsin D (CTSD). 
Elevated serum levels of both proteins appear to correlate with the severity of the 
neurological deficit and appear to be specific for the NP-C disease and therefore to be a 
potentially usefull for diagnosis.  
 In 2011, two adult patients with NP-C disease were subjected to the 
Magnetization Transfer Ratio (MTR), an advanced technique that allows the assessment 
of the integrity of macromolecules forming the brain tissue (Zaaeaoui et al., 2011). This 
technique revealed damages in the grey matter of the cerebellar, thalamic and lenticular 
nuclei in both patients. It is reasonable that the damage of the grey matter is initially localized 
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in cerebellum and spreads thereafter to the frontotemporal cortex in the later stages of the 
disease. This hypothetical course of the disease correlates with the clinical features of the 
disorder in which initially are present sub-cortical signs (dystonia, dysarthria, dysphagia) and 
later cognitive impairment. 
 Recently, some authors have tried to set a battery of tests suitable for the 
neuropsychological evaluation of the NP-C disease (Klarner et al., 2007). Because the 
cognitive changes that occur in patients with NP-C disease are similar to those occurring in 
elderly patients with dementia, similar tests can be used for both disorders. The Trial Making 
Test (A & B) and the verbal fluency tests are sensitive indicators of the early stages of the 
NPC. In later stages of the disease patients have a reduced performance in Corsi Block-
Tapping, Mini Mental State Exanimation (MMSE) and Clock Drawing. Due to their 
compromised motor skills Grooved Pegboard, Trail Making and Mosaic's tests are not 
suitable for evaluation in the advanced stages of the disease. 
 
1.7. Differential diagnosis  
 
 For early onset NP-C disease forms the differential diagnosis should consider all 
possible causes of cholestatic jaundice, such as idiopathic neonatal hepatitis.  
 Among other lipid storage diseases, the differential diagnosis must be performed 
especially with NP-B, which presents in bone marrow similar foam cells, and Gaucher 
disease, which can present many symptoms in common including ataxia, VSGP and 
splenomegaly (Pandi et al., 2014).  
 For late onset forms, the differential diagnosis should be performed from all those 
conditions that can causes the most prominent neurological signs (Schiffmann, 1996; Wraith 
et al., 2009; Vanier, 2010).  
 
1.8. Prognosis   
 
 Generally, NP-C patients die prematurely between 10 and 25 years of age 
(Vanier, 2010). However, the rate of disease progression and life expectancy vary greatly 
depending on the age of onset and the severity of symptoms.  
Patients with pre/peri-natal onset, suffering from a severe form of neonatal cholestasis, 
usually die within 5 month of age.  
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Subjects with severe early infantile onset die within 5 years of age, while, in late infantile 
onset form the survival varies between 7 and 12 years of age. The juvenile onset forms 
display a more variable life span; some patients surviving up to 30 years of age (Vanier, 
2010). Finally, in cases with adolescent/adult onset the life expectancy is even better; some 
patients, who show few neurological symptoms, survive until the sixth or seventh decade of 
life (Trendelerbug et al., 2006; Dvorakova et al., 2006).  
 Although the precise causes of death are not always reported in the literature, 
historical and epidemiological data indicate that patients typically die because of bronchial 
pneumonia, infections and choking due to the repeated aspirations caused by the 
progressive dysphagia (Kelly et al., 1993; Jan et al., 1998).  
 
1.9. Treatments  
 
 In the absence of a specific treatment for the NP-C disease, therapeutic 
approaches attempt to delay the onset and progression of cellular damage and symptoms. 
In recent years, several therapeutic approaches have been proposed. The most promising 
are presented below. 
 
 Symptomatic therapy involves the use of standard drug treatments for 
gastrointestinal and neurological manifestations. Dysphagia could cause malnutrition and 
food aspiration; dietary manipulation, including softening and thickening of food as well as 
antibiotics treatment to avoid aspiration pneumonia, are widely used. In severe cases it is 
advisable to perform a gastrostomy to ensure proper daily caloric intake. Atropine can control 
the heavy drooling of saliva. Seizures and cataplexy can by controlled using antiepileptic 
drugs and tricyclic antidepressant or CNS stimulants, respectively. Dystonia and tremors 
respond well to anticholinergic drugs, trihexyphenidyl, benzodiazepines, and Gamma-
aminobutyric acid derivatives. Insomnia can be treated using Melatonin. These treatments 
are usually helped by physiotherapy, physical occupational and language therapy (Alobaidy, 
2015).  
 
 Miglustat. Miglutat (Zavesca® and Brazaves®) is a small water-soluble 
iminosugar derived from the glucosidase inhibitor deoxynojirimycin (Lysegn-Williamson, 
2014). Up to now, it represents the only drug approved for the treatment of NP-C disease 
neurological manifestations in EU countries as well as in Argentina, Australia, Brazil, 
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Canada, Chile, Colombia, Japan, Mexico, New Zealand, Russia, South Korea, Switzerland 
and Turkey (Lysegn-Williamson, 2014). This molecule inhibits the synthesis of 
glucosylceramide synthase, the enzyme involved in the first step of glycosphingolipid 
synthesis and inhibits the glycosphingolipid synthesis (Platt et al., 1994; Lysegn-Williamson, 
2014). In both feline and murine models of NP-C disease, miglustat reduces 
glycosphingolipid accumulations, delays the onset of neurological manifestations and 
increases the lifespan (Zervas et al., 2001; Lachmann et al., 2004). The oral administration 
of miglustat to NP-C patients improves the lipid trafficking and storage, protects from 
oxidative stress and axonal degeneration, and stabilizes the neurological manifestations 
(Lachmann and Platt, 2004; Maalouf et al., 2011; Ribas et al., 2012). However, the 
administration causes gastrointestinal disorders such as diarrhea and flatulence (Patterson 
et al., 2007).  
 
 Substrate reduction therapy. The main substrate reduction approaches include 
the administration of statins and/or ezetimibe and a low-cholesterol diet (Rosenbaum and 
Maxifield, 2011). These treatments reduce the load of peripheral cholesterol (Patterson and 
Platt, 2004; Liu et al., 2010).  In particular, statins inhibit the synthesis of endogenous 
cholesterol by acting on hydroxymethylglutaryl-CoA reductase, an enzyme that converts 
HMGR into mevaloic acid, a precursor of cholesterol. Instead, ezetimibe selectivity inhibits 
the intestinal absorption of cholesterol taken by diet and the biliary cholesterol present in the 
brush borders of the small intestine, without causing the side effects typical of the resins 
binding bile acids.  The two drugs can be co-administered (Rosenbaum and Maxfield, 2011). 
An alternative strategy of substrate reduction for lowering visceral symptoms is the 
inhibition of cholesterol synthesis via the hydrolysis of cholesterol esters mediated by 
LAL. It has been shown that this inhibition causes a significant reduction of cholesterol 
storage in human NPC-defective cells (Rosenbaum et al., 2009). However, the substrate 
reduction therapy does not correct the insufficient steroidogenesis, which represents an 
important feature of NP-C disease neuropathology (Griffin et al., 2004; Rosenbaum and 
Maxfield, 2011). 
 
 Acid sphingomyelinase. Recent investigations have focused on the role of the 
enzyme acid sphingomyelinase (ASM) in the pathogenesis of NP-C disease. In fact, despite 
the absence of alterations of the ASM gene, the levels of this enzyme activity are decreased 
in NP-C patients compared to normal subjects (Devlin et al., 2010). The recovery of the 
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levels of ASM activity by recombinant enzyme re-introduction has led to the reversal of the 
classic phenotype of NPC1 cells. This observation encourages the use of parallel treatment 
approaches acting on different aspects of the NPC disease, and on the sphingolipid storage 
associated with its neuropathology. 
 
 Chemical Chaperones. The three-dimensional control of the organization of 
proteins by chemical chaperones has been proposed as a treatment for a variety of disease, 
including lysosomal storage disorders (Balch et al., 2008). Cultured cells obtained from a 
mouse model of NPC1 carrying the I1061T mutation and treated with chemical chaperones 
have shown an improvement of the folding of NPC1 protein and a rescue of lysosomal 
trafficking (Gelsthorpe et al., 2008). Arimoclomol is a drug that induces the expression of 
an important group of chaperone proteins known as heat shock proteins (HSPs). It has been 
shown that in several neurodegenerative diseases, including amyotrophic lateral sclerosis 
(ALS), the upregulation of HSPs reduces the cellular damage, prevents protein misfolding, 
aggregation and abnormal degradation (Kalmar et al., 2014). Also, the HSPs upregulation 
improved the intracellular accumulation of lipids in NP-C cells (Kierkegaard et al., 2010).  
Presently, an observational study of Arimoclomol effects in NP-C patients is ongoing 
(ClinicalTrials.gov identifier: NCT02435030). 
 
 Curcumin. It has been shown that the active principle of turmeric, known as 
curcumin, increases cytosolic calcium levels in vitro and enhances the cellular phenotype of 
Npc1-/- mice (Lloyd-Evans et al., 2008). In addition, Lloyd-Evans and coll. reported that 
curcumin increases of 35% the survival of Npc1-/- compared to wild-type mice. However, a 
second study using the same mouse model, reported a lengthening of life span of 19%, 
leading to the conclusion that curcumin is not a highly efficacious treatment for NP-C disease 
(Borbon et al., 2012).  
 
 Histone deacetylase (HDAC) inhibitors. HDACs are a family of enzymes that 
play a key role in a multitude of biological processes by influencing gene transcription. It has 
been shown that HDACs increase the expression of NPC1 protein, thus correcting the 
intracellular accumulation of cholesterol in human fibroblasts (Munkacsi et al., 2011; Pipalia 
et al., 2011). In addition, the treatment with the HDAC valproic acid (VPA) has been shown 
to promote the differentiation of neural stem cells in Npc1-/- mice (Kim et al., 2007).  
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 Acetyl-DL-leucine. Recently, the administration of a modified amino acid, known 
as Acetyl-DL-leucine was tested in 12 NP-C patients, whose age varied between 13 and 32 
years.  An improvement in cerebellar signs of disease, such as ataxia was observed after a 
month of treatment. Also, this treatment was well tolerated by patients, with only one of them 
developing transient dizziness as side effect. This makes this amino acid one of the most 
promising treatments (Bremova et al., 2015; Papandreou and Gissen, 2016).  
 
 Cyclodextrins are cyclic oligosaccharides formed by a hollow cone-like toroid 
structure with a hydrophobic cavity and a hydrophilic exterior and composed by several liked 
glucopyronose moyeties. The number of glucopyronose moyeties determinates the 
cyclodextrins nomenclature () as well as its cavity size (Figure 13) (Liu, 2012). These 
structural features make cyclodextrins useful molecules to solubilize various 
pharmaceuticals (Davis and Brewster, 2004).  
 
 
       Figure 13. Chemical structure of cyclodextrins.  
 
 
 The discovery of their efficacy in treating NP-C disease has been accidental. In 
fact, a single subcutaneous injection of the neurosteroid allopregnanolone (ALLO), which 
levels are reduced in NP-C disease, solubilized in 20% 2-hydroxypropyl-β-cyclodextrin (CD) 
increased life span and improved neuropathology in Npc1-/- mice (Griffin et al., 2004).  
Several subsequent studies have shown that CD injections alone were responsible for the 
effects of CD+ALLO administration (Liu et al., 2010, Davidson et al., 2009). These 
investigations have demonstrated that a single injection of CD (4 mg/Kg body weight) 
performed at post-natal day 7, significantly reduced the NPC-phenotype in brain, liver, 
spleen, lungs and bone marrow and extend the life span by nearly 50% of Npc1-/- mice (Liu, 
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2012). Also, CD treatment decrease cholesterol and glycosphingolipids storage and 
prevents Purkinje cells death on both feline and murine models of the disease (Xie et al., 
2011; Davidson et al., 2009; Raminez et al., 2010; Liu, 2012; Vite et al., 2015).  
However, preclinical studies carried out in animal models, showed that young animals 
responded better to CD treatment than the older ones (Liu et al., 2008; Vite et al., 2015). 
The closure of the blood-brain barrier that cyclodextrins are not able to cross because of 
their chemical structure, likely explains this finding (Liu, 2012).  
 Despite their inability to cross membranes, CDs can be delivered via pinocytosis 
to LE/LY, where they can replace the function of NPC1 and NPC2 proteins (Rosenbaum et 
al., 2010b) and promote cholesterol esterification by acetyl CoA:acyl transferase (Abi-
Mosleh et al., 2009). The exact nature of CD’s mechanism of action to replace NPC1 and 
NPC2 function in LE/LY is yet to be determined.  
One possibility would be that CD solubilizes cholesterol and thus promote its efflux via 
vesicular transport. Alternatively, CD action might act catalytically to shuttle cholesterol from 
LAL directly to the limiting membrane of the lysosome, bypassing the potential requirement 
for NPC2-NPC1 interaction (Rosenbaum and Maxfield, 2011). Once delivered to the luminal 
leaflet of the limiting membrane, cholesterol can then spontaneously flip to the cytosolic 
leaflet and be carried away to various compartments within cells, via still poorly characterized 
transport processes (Maxfield and Menon, 2006) (Figure 14). 
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Figure 14. Model for cyclodextrin action in cholesterol efflux from late 
endosomes/lysosomes. In normal cells, cholesteryl esters are hydrolyzed by LAL to 
produce free cholesterol and fatty acid (1), then free cholesterol is transferred to NPC2 (2), 
and subsequently to the N-terminal domain of NPC1 (3). Free cholesterol is then delivered 
to the luminal leaflet of the limiting membrane of late endosomes/lysosomes (4), where it 
can spontaneously flip to the cytosolic side (5) and then be carried to its various destinations 
in the cell by cytoplasmic carriers (6). In the absence of functional NPC2 or NPC1, 
cyclodextrins can replace their functions in promoting cholesterol efflux (7, 8), bypassing 
steps 2–4 (Rosenbaum and Maxfield, 2011). 
 
 
 In 2010 the U.S. Food and Drug Administration (FDA) approved the CD 
compassionate use in humans and in recent years it has been administered to a number 
of pediatric patients (Garcìa-Robles et al., 2016)  
These studies have shown that treatment with CD stabilizes or improves the health of young 
patients (Hastings, 2010; Matsuo et al., 2013; Matsuo et al., 2014; Maarup et al., 2015).  
 In 2016, was published the first study on treatment with CD in two female adult 
patients that received NP-C disease diagnosis only several years later the onset of first 
symptoms (Garcìa-Robles et al., 2016). In both patients CD were intrathecally administrated 
in the framework of FDA compassionate use clinical study protocol (Hastings, 2010). 
Although the treatment duration was relatively short, it didn’t stabilize or decrease the 
progression of the disorder, resulting in a worsening of neurological symptoms in both 
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patients. In addition, a patient refused dropped out of the treatment while the other 
developed severe adverse reactions, such as toxic meningitis, probably due to method of 
CD administration (Garcìa-Robles et al., 2016).  
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Chapter II  
 
The cerebellum: involvement in NP-C1 
disease 
 
2.1. The cerebellum 
 
The cerebellum (“little brain”) is the part of central nervous system (CNS) located 
in the posterior cranial fossa (Buckner, 2013). Macroscopically the cerebellar anatomy 
consists of two hemispheres connected by a midline structure known as vermis (Figure 
15A). 
The cerebellum is divided into three lobes by two deep fissures: anterior, posterior 
and flocculonodular lobes. The primary fissure separates the anterior and posterior lobes, 
whereas the postero-lateral fissure divides the posterior from the flocculonodular lobe.  More 
superficial fissures divide these regions in sub-lobules, known as folia, which represent the 
gyri on the cerebellar surface.   
All mammals have a similar 10-folia structure, denoted by Roman numerals, suggesting that 
foliation is genetically determined (Sudarov and Joyner, 2007; Cerminara et al., 2015) 
(Figure 15B). 
Anatomically, the cerebellar cortex is formed by 8 different neuronal cell types 
(Purkinje, Golgi, Lugaro, Granule, Basket, Stellate, Unipolar brush and Candelabrum cells) 
and glial cells (Bergman glia, protoplasmic and fibrous astrocytes, oligodendrocytes and 
microglia) (Cajal, 1911; Lainè and Axelrad, 1994; Mugnaini and Floris, 1994; Vela et al., 
1995; Buffo and Rossi, 2013). 
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In the brain of adult mammals these cells are arranged in three layers (Figure15C): 
 
- The Molecular layer (ML), located under the pial surface and formed by the 
dendritic tree of several neurons (Purkinje, Golgi, candelabrum cells), by the 
cells bodies and dendritic tree of basket/stellate interneurons, Bergmann glia 
fibers and parallel/climbing fibers; 
- The Purkinje cell layer (PCL) contains the soma of Purkinje cells, Bergmann 
glia and candelabrum cells, part of the dendritic tree of Golgi cells and it is 
crossed by parallel/climbing fibers; 
- The Internal granule layer (IGL), also called Granule cell layer (GCL), contains 
the cell bodies of granule neurons and Golgi cells, Lugaro cells, unipolar brush 
cells, Purkinje cell axons, mossy/climbing fibers, protoplasmic astrocytes. The 
granule layer parallel fibers also originate in this layer. 
 
Beneath the GCL resides the white matter (WM), where the cerebellar deep nuclei and 
fibrous astrocytes are located. Instead, microglia and oligodendrocytes are localized in both 
cortical layers and white matter (Vela et al., 1995; Buffo and Rossi, 2013; D’Angelo and 
Casali, 2013). 
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Figure 15. Cerebellar cytoarchitecture (Cerminara et al., 2015). 
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2.1.1. Cerebellar neurons 
 
The most important neuronal class is the GABAergic Purkinje cells (PCs) that 
represent the sole output of cerebellar cortex (D’Angelo and Casali, 2013). The cells bodies 
of PC (~18 m diameter in mouse) have a flask shape and are arranged in the PCL 
monolayer. Multiple primary dendrites emerge from the neck of PC cell body and extend 
upward contributing to the formation of the ML (Weber and Schachner, 1984; Nakagawa et 
al., 1998). 
Each PC receives over 100.000 inputs from parallel fibers (PFs) and inhibitory interneurons, 
and about 500 inputs from a single climbing-fiber (CF) (Ito, 2006) and has a single axon 
emerging from the bottom of the cell body, descending through the GCL and WM and 
terminating in one of the deep cerebellar nuclei (Monsivais et al., 2005). 
To send the appropriate output to deep cerebellar nuclei, PC cells need to receive 
an appropriate excitation/inhibition by different classes of cerebellar neurons. Among these, 
Granule neurons (GNs) represent the most abundant neuronal population of the 
cerebellum (Fox and Barnad, 1957). They are characterized by a small cell body (5-8 m 
diameter) from which emerge 4/5 dendrites that receive excitatory and inhibitory inputs from 
mossy fibers (MF) and Golgi cells. These synapses give rise to typical structures known as 
glomeruli (Buffo and Rossi, 2013).  GNs are provided with unmyelinated axons extending 
upward to the upper ML, where they split in two arms each and elongate horizontally to form 
the so called parallel fibers (Vranesic et al., 1994). Being glutamatergic, GNs exert excitatory 
effects on PCs, whereas receive inhibitory inputs from Golgi cells and excitatory input from 
Unipolar brush cells.  
The Golgi cells (GCs) are the most common and numerous GABAergic 
interneurons of the GCL, manly located in the upper GCL (~6000 in cat; ~1200 in humans; 
~400 in rats) (Palkovits et al., 1971; Andersen et al., 1992; Korbo et al., 1993; D’Angelo and 
Casali, 2013). GCs are landmarked by a soma of irregular shape (diameter 10-30 m), a 
branched axon, some basal dendrites that form synaptic contacts within the GCL and by 
two/three apical dendrites that ascend to the molecular layer and form synaptic contacts with 
parallel fibers (Dieudonnè, 1999; Barmack and Yakhnitsa, 2008). It has been shown that GC 
receive excitatory inputs from MF and GABAergic or mixed GABAergic/glycinergic inputs 
from Basket/Stellate interneurons and Lugaro cells, respectively (Dumoulin et al., 2001; 
D’Angelo and Casali, 2013). GCs represent the sole output that inhibits GNs in cerebellar 
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glomeruli through both feedforward and feedback loops, regulating and controlling the MF-
GN synapses (Rossi et al., 2003; D’Angelo and Casali, 2013).  
The Unipolar brush cells (UBCs) are the only glutamatergic interneurons of 
cerebellar cortex, mainly localized in the lobule IX (~24%) and X (~42%) (Altman and Bayer, 
1996; Sekerkovà et al., 2004). They are very small neurons that present a single thick and 
stubby dendrite which terminates in a brush-like spray (Schilling et al., 2008). UBCs receive 
input from a single MF that provides vestibular afferents and send an excitatory input to GNs. 
Their single axon takes a tortuous course in the GCL and shapes a rosette-like protrusions 
that form the central component of glomeruli (Schilling et al., 2008). It has been shown that 
their principal function is to coordinate the synchronized activity of a group of GNs, which in 
turn regulate the activity of a small group of PCs (Nunzi et al., 2001). PCs also receive 
GABAergic inputs from Basket/Stellate interneurons and Lugaro cells.  
The Basket and stellate cells (BC/SCs) in turn receive excitatory inputs from 
parallel fibers and, in addition to PCs, also inhibit GCs (Dumoulin, 2001; Cameron et al., 
2009). It is unclear whether they represent two distinct classes of cells; currently their 
subdivision is based on morphological fearures and their localization in the ML (Schilling et 
al., 2008). Basket cells have a stellate shape and localize in lower ML (Rakic, 1972). They 
are slightly more numerous than PCs (about 15-20%) and their dendritic tree does not 
extends beyond the lower ML and is provided with scattered spines. Their axons have 
numerous ascending collaterals that forms a kind of basket surrounding the soma of PCs 
(Rakic, 1972). Stellate cells are mostly located in the upper ML and even if dendrites and 
spines are similar to those of the BC, the trajectory and the branching of their axons confer 
to these cells a star-like shape (Eccless, 1967; Rakic, 1972). Lugaro cells (LCs) represents 
1/3 of inhibitory interneurons of GCL in mice, while in other species, such as rats and cats, 
they seem to be less abundant (Sahin and Hockfield, 1990; Dieudonnè and Domulin, 2000; 
Simat et al., 2007). Like GCs, they are mainly located in the upper GCL and are 
characterized by a fusiform cell body, whose size is iin between that of GN and GC (Schilling 
et al., 2008). A single fiber originate from the LC cell body, reaches the ML and emanates 
two pairs of long dendrites which send GABAergic and a GABAergic/glycinergic inputs to 
PC and BC/SC, respectively (Lainè and Axelrad, 1996; Dieudonnè and Dumoilin, 2000) 
In the GCL they provide inhibitory inputs to GC: it was estimated that one LC takes contacts 
with ~100 GCs (Dieudonnè and Domulin, 2000). LCs are the primary target of serotoninergic 
input in the cerebellar cortex and also receive inputs from collateral axons of PC and Basket 
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interneurons (Fox and Barnard, 1957; Palay and Chan-Palay, 1974; Dieudonnè and 
Domulin, 2000). 
In 1994, an additional class of cerebellar neurons, known as Candelabrum cells 
(CCs), was discovered (Lainè and Axelrad, 1994). These cells are characterized by a small 
and pyriform soma located between PC soma. CCs have 1-2 branches dendrite ascending 
into ML and 3-5 short dendrites projecting in the GCL (Lainè and Axelrad, 1994; Schilling et 
al., 2008). Lainè and Axelrad (1994) named these cells “candelabrum” because their axon 
projects horizontally to ML and emit here multiple branches that ascend vertically for the 
entire ML. Some evidence has shown that they are distributed in all parts of the cerebellar 
cortex and that they use a GABA/glycine transmission (Schilling et al., 2008).  However, their 
afferents and efferents have not yet been identified, even if their dendritic structure suggests 
that CCs may receive inputs by climbing/parallel fibers, ascending GN axons and BC/SC 
and send output to PC dendrites (Schiling et al., 2008). 
Interestingly, both histological and immunohistochemistry analyses have suggested 
that other neuronal type exist in cerebellar cortex, although they have been not yet 
characterized. In 2003, it has been shown that the incubation of mouse cerebella with NeuN 
antibody marks a class of neurons located in the lower ML. This study also established that 
NeuN does not stains cerebellar inhibitory interneurons such as PCs and UBCs (Weyer and 
Schilling, 2003). 
In addition, at least two additional neuronal types might exist; the first are Npas3-
positive, while the second are cat-301-positive. Both are located in the GCL but are distinct 
from other neurons actually known (Erbel-Sieler et al., 2004; Crook et al., 2007; Schiling et 
al., 2008).   
 
2.1.2. Cerebellar glia 
 
Based on their morphology and anatomical location cerebellar astrocytes can be 
divided into two main classes: Bergmann glia and intraparenchymal astrocytes 
(protoplasmic and fibrous astrocytes) (Buffo and Rossi, 2013). 
Bergmann glial (BG) is a highly diversified unipolar astrocyte type, essential for 
neuron migrations during development and performing an important role for extracellular ion 
homeostasis (Wang et al., 2012), synapse stability (Iino et al., 2001; Saab et al., 2012), 
plasticity (Balakrishnan and Bellamy, 2009; Balakrishnan et al., 2014), and metabolic 
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function and neuroprotection (Poblete-Naredo et al., 2011; Jakoby et al., 2014) in the adult 
cerebellum.  
BG cell bodies are located around the PCs bodies and extend several fibers that traverse 
the ML and terminate in the pial surface, taking contacts with the blood vessels of the ML 
(Buffo and Rossi, 2013). The shaft fibers form a palisade-like glial framework.  
The dendritic tree of each PC is covered with longitudinal glial columns made by several BG 
fibers (Yamada and Watanabe, 2002). It was estimated that in rodent cerebellum there are 
~8 BG cells per PC and that each BG cell enwraps 2000-6000 PC synapses (Reichenbach 
et al., 2010). Thus, BG processes provide a structural substrate for the directional growth of 
PC dendrites, inﬂuencing the shape of the dendritic tree (Lordkipanidze and Dunaevsky, 
2005; Buffo and Rossi, 2013). 
Protoplasmic astrocytes localize in the GCL and display the classical stellate 
shape with several stem branches that give rise to many finely branching processes in a 
uniform globoid distribution (Cajal, 1909). 
Fibrous astrocytes localize in the white matter and are characterized by many long 
fiber-like processes (Cajal, 1909) (Figure 16). 
 
 
 
 
Figure 16. Intraparenchymal astrocytes morphology. 
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Both types of astrocytes contact blood vessels and form gap junctions with the distal 
processes of neighboring astrocytes (Peters et al., 1991).  
Recent findings show that astrocytes produce and release several molecular 
mediators, such prostaglandins (PGE), nitric oxide (NO), and arachidonic acid (AA), that 
increase or decrease blood vessel diameter and blood flow in response to neuronal activity 
changes (Gordon et al., 2007; Iadecola and Nedersaard, 2007; Kohler et al., 2009). 
Astrocytes contribute to CNS metabolism taking up glucose from blood vessels and 
providing energy metabolites to different neural populations in both gray and white matter. 
Electron microscopy analyses reveled that, while processes of fibrous astrocytes take 
contacts with nodes of Ranvier (Peters et al., 1991), the processes of protoplasmic 
astrocytes borders with a small group of GN and enwrap the glomeruli to isolate synaptic 
complexes and mossy fibers (Palay and Chan-Palay, 1974; Hoogland and Kuhn, 2010). 
Each protoplasmic astrocyte extends five-to-ten main stem branches, each of which 
gives rise to many finely branching processes that are distributed throughout the astrocyte 
domain in the gray matter and contact several hundred dendrites from multiple neurons 
enveloping about 100.000 synapses (Bushong et al., 2002; Ogata and Kosaka, 2002; 
Halassa et al., 2007). 
Astrocytes express Aquaporin 4 (AQP4) water channel (regulating the fluid 
homeostasis, Seifert et al., 2006) and transporters for glutamate, GABA and glycine 
(removing the neurotransmitters for the synaptic cleft (Sattler and Rothstein, 2006). 
Astrocytes release energy substrates, neurotransmitters, purines, growth factors (BDNF, 
TNF) and neurosteroids and express channels for both potassium and sodium. Their 
excitation, caused by the increase of intracellular calcium concentration, is required for 
astrocyte-astrocyte and astrocyte-neuron communication (Sofroniew and Vinters, 2010). 
During neurodevelopment astrocytes release signaling molecules, such as 
thrombospondin, essential for the development of synapses and induce the expression of 
complement C1q that plays a key role in microglia-mediated synaptic pruning 
(Christopherson et al., 2005; Ullian et al., 2001; Stevens et al., 2007; Barres, 2008). The 
functions of astrocytes are summarized in Figure 17. 
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Figure 17. Astrocyte functions in healthy CNS (Adapted from Sofroniew and Vinters, 2010). 
 
 
In response to CNS injury and disease, astrocytes exhibit different molecular, 
cellular and functional changes known as reactive astrogliosis (Sofroniew, 2009). Reactive 
astrogliosis can be mild or severe. Mild reactive astrogliosis is landmarked by the up 
regulation of glial fibrillary acidic protein (GFAP) expression, hypertrophy of the cell body 
and processes with preservation of astrocytes individual domains and little or no astrocyte 
proliferation (Sofroniew, 2009). In the severe form, there is a strong up-regulation of GFAP 
expression, more pronounced hypertrophy of the cell body and significantly increased 
proliferation, causing the disruption of individual astrocytes domains. 
Oligodendrocytes are a type of highly specialized glial cells, whose main role is the 
production of the myelin sheath that electrically insulates axons maximizing the efficiency of 
action potential propagation (Liu and Zhou, 2013). While oligodendrocytes sit in the white 
matter and in all cortical layers, myelin formation is restricted to white matter and GCL (Palay 
and Chan-Palay, 1974; Reynolds and Wilkin, 1988). The only myelinated processes of the 
molecular layer are PC axons (Palay and Chan-Palay, 1974). It has been shown that PC 
axons are myelinated from their terminal field to the cell body, while cortical afferents 
(olivocerebellar axons and mossy fibers) are myelinated in anterograde manner (Buffo and 
Rossi, 2013). 
Microglia are the only resident macrophages of the CNS and their density varies 
within different areas (Vela et al., 1995; Ginhoux and Prinz, 2015). Microglia exerts a crucial 
role in both CNS immune defense and homeostasis maintenance (Ginhoux and Prinz, 2015). 
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Microglia also contributes to brain homeostasis by controlling neuronal 
proliferation/differentiation and influencing the synapses formation (Lawson et al., 1990; 
Perry, 1998; Hughes, 2012; Blank and Prinz, 2013). 
 
2.2. Origin of cerebellar neurons and glia   
 
Neurons and glial cells of cerebellum arise from two different germinal zones: the 
dorsomedial ventricular zone (VZ) along the fourth ventricle and the free margin of the 
hindbrain at the interface between the roof plate and the dorsal neuroepithelium of 
rhombomere 1, known as rhombic lip (RL) (Sotelo, 2004; Kita et al., 2013). Progenitors 
having a radial glia-like morphology are present in both VZ and RL and give rise to almost 
all cell types (Kita et al., 2013).   
PCs, GCs, LCs, BC/SCs, small-diameter DCNs, intraparenchymal astrocytes, BG 
cells and some oligodendrocytes originate from the VZ, while UBCs, GNs and large-diameter 
DCNs originate from RL. The origin of CCs is still unknown. These different cell types begin 
to differentiate at different stages of embryonic life in mice (Kita et al., 2013) (Figure 19). 
 
 
 
Figure 19. Origin of cerebellar neurons and glia. Green bars indicate that progenitors are 
self-renewing at indicated stages. Orange bars show stages at which progenitors generate 
differentiated cells. GC/LC, Golgi cell and Lugaro cell; PC, Purkinje cell; SC/BC, stellate and 
basket cell; BG, Bergmann glia; As, astrocyte; Ol, oligodendrocyte; sDN, small-diameter 
deep nuclei neuron; lDN, large-diameter deep nuclei neuron; grC, granule cell (Kita et al., 
2013). 
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Neurons of the adult cerebellum follow a temporal sequence of differentiation. 
Glutamatergic projection neurons (NP), GABAergic nucleo-olivary projection neurons (NO) 
and PCs differentiate in the early embryonic life, while local interneurons (of both 
neurotransmitter phenotypes) differentiate in late embryonic and early postnatal life. 
GABAergic interneurons are generated according to an inside-out sequence, occupying the 
deep nuclei first, and then the GCL and ML (Carletti and Rossi, 2008; Consalez and Hawkes, 
2012). 
 
 
 
Figure 20. Temporal sequence of differentiation for the main types of cerebellar 
neurons (Consalez and Hawkes, 2012). 
 
Although both BG and parenchymal astrocytes originate from the radial glia of VZ 
during late embryonic and postnatal development (Cajal, 1911; Miale and Sidman, 1961; 
Altman and Bayer, 1996; Sekerkova´ et al., 2004; Mori et al., 2006), they have a different 
natural history.  
BG arise from the direct transformation of radial glia and continue to proliferate during the 
late embryonic and early postnatal life to match the simultaneous expansion of cerebellar 
cortex. Part of VZ radial glia continues to proliferate and then migrates in the PWN where it 
continues to divide and eventually acquires the mature trait of both fibrous and protoplasmic 
astrocytes (Buffo and Rossi, 2013). It is still unclear whether PWN progenitors contribute to 
generate BG or, vice versa, if proliferating BG can differentiate in intraparenchymal 
astrocytes (Miyake et al., 1995; Yuasa, 1996) (Figure 21). 
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Figure 21. Origin of intraparenchymal astrocytes and BG. Both astrocyte classes 
originate from the radial glia of the VZ. Part of VZ radial glia continues to proliferate and then 
migrates in the PWN where it continues to divide, finally acquiring the mature trait of 
intraparenchymal astrocytes (green arrows on the left side of the picture). It is unclear 
whether PWN progenitors can differentiate in BG (dashed green arrow on the left side of the 
figure). BG arises from the direct transformation of BG arising from the direct transformation 
of radial glia and continues to proliferate during the late embryonic and early postnatal 
development to match the simultaneous expansion of cerebellar cortex (red arrows on the 
right side of the figure). It is not clear whether proliferating BG may also differentiate in 
intraparenchymal astrocytes (dashed red arrows on the right side of the figure) (Buffo and 
Rossi, 2013). 
 
Although some oligodendrocytes originate from the radial glia of the VZ, they mostly derive 
from an extracerebellar source (Buffo and Rossi, 2013). 
Besides oligodendrocytes, also microglia have an extracerebellar origin. Several 
genetic mapping studies have demonstrated that microglia mainly arise from the yolk sac 
(YS) primitive macrophages (Ginhoux et al., 2010; Hoeffel et al. 2012; Schulz et al., 2012; 
Kierdorf et al., 2013; Perdiguero et al., 2015).  
During embryonic life, microglia precursors use three different routes to invade the CNS 
(Jordan and Thomas, 1988; Cuadros et al., 1994; NavascueÂs et al.,1996): 
- Meninges, by traversing the pial surface; 
- Ventricles, by traversing the ventricular layer; 
- Blood circulation, by traversing the endothelial wall; 
among which the first one is the most common one (Cuadros et al., 1997). 
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2.3. Interaction between Bergmann glia and Purkinje cells 
 
PC migration is physically supported by the processes of radial glia and involves 
several adhesion molecules, including reelin released by the EGL, leading them to reach 
specific cortical domain (Rakic et al., 1970; Yuasa et al., 1991, 1996). Recent studies have 
shown that some PCs migrate tangentially, initially, and interact with BG only at later stages 
(Yamada and Watanabe, 2002; Miyata et al., 2010). 
In mice, until embryonal day 14 (E14) glial precursors display the morphology of 
radial glia, with cells bodies localizing in the VZ and radial fibers extending to the mantle 
zone. Between E14 and E15 PCs are in contact and lean against radial glia fibers, 
suggesting that radial glial cells are involved in contact guidance of PC migration (Yamada 
and Watanabe, 2002). Between E15 and PN7, the radial glia becomes BG by losing apical 
process while cell bodies migrate through the cortex (Buffo and Rossi, 2013). The migration 
of radial glia cell bodies slows down the migration of PCs; first, PCs move radially to the pial 
surface giving rise to the PC plate (PCP) below the EGL, whereas BG send several radial 
processes to the pial surface (Altman et al., 1997; Sotelo et al., 2012). Subsequently PCs 
migrate from the PCP to the bottom of ML forming the PCL. During the second and third 
postnatal weeks BG undergoes to cytoarchitectonic changes: the shaft fibers extend 
lamellate processes changing the palisade-like radial organization to a reticular glial 
meshwork (Yamada et al., 2000).  
The dynamic transformation of BG fibers proceeds in concomitance with 
dendritogenesis and synaptogenesis of PCs, that in rodents are active in the second 
postnatal week of life (Altman, 1972b; Yamada and Watanabe, 2002). Thus, the rod-like 
domain of BG fibers provides a physical, trophic and structural substrate for PC growing 
dendrites, while the reticular transformation is related to structural maturation of newly 
formed PC synapses by glial covering (Yamada and Watanabe, 2002).  
In particular, BG processes almost completely enwrap PF-PC synapses as well as CF-PC 
synapses (Palay and Chan-Palay, 1974; Spacek, 1985; Xu-Friedman et al., 2001; Yamada 
and Watanabe, 2002). At the molecular level, this interaction is mediated by 
phosphacan/6B4 proteoglycan, a chondroitinsulphate proteoglycan expressed by PCs 
(Maeda et al., 1992). Phosphacan is a component of the protein tyrosine phosphatase zeta 
(PTP) receptor that mediates Pleiotropin (PTN) and Midkine (MN) signalling (Maeda et al., 
1996, 1999), which are expressed and released by BG (Matsumoto et al., 1994; Wewetzer 
et al., 1995).  
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The activation of BG can be elicited by the stimulation of both PFs and CFs, which 
causes an increased intracellular calcium concentration in BG processes (Clark and 
Barbour, 1997, Bergles et al., 1997; Grosche et al., 1999; Iino et al., 2001). CFs-mediated 
stimulation increases the expression of GLutamate ASpartate Transporter (GLAST) by 
BG; GLAST removes glutamate from the synaptic cleft, preventing glutamate spillover 
between adjacent PCs (Bergles et al., 1997; Takayasu et al., 2009). Within the brain, BG 
expresses the highest density of GLAST; there are roughly 18000 molecules of GLAST for 
each m3 of tissue, while other glial cells express 4700 molecules per m2 (Lehre and 
Danbolt, 1998). GLAST is expressed from the earliest stages of development (Lehre et al., 
1995), but the concentration increases significantly in concomitance with PC synaptogenesis 
(Ullensvang et al., 1997). In light of these findings, GLAST can be considered as a useful 
marker to analyze the structural relationship between BG and PCs development (Yamada 
et al., 2000).  
After the uptake into BG, glutamate is converted by the enzyme Glutamine 
synthetase to glutamine and recycled back to synapses for reconversion into active 
transmitter (Sofroniew and Vinters, 2010).  
In addition to GLAST and glutamine synthetase, BG also expresses high Calcium 
permeable a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate 
receptors. It has been shown that glutamate released by PF/CF terminals acts through 
calcium-permeable AMPA receptors to regulate the degree of perisynaptic envelopment by 
BG. This, in turn, modulates the rate of glutamate removal from the synaptic cleft affecting 
the dynamics of synaptic signaling (Buffo and Rossi, 2013).  
 
2.4. The scaffolding role of Bergmann glia during granule neuron and 
Basket/Stellate interneuron migration  
 
The scaffolding activity of BG during GN migration is probably the most important 
and most studied example of glial-guided neuronal migration (Rakic, 1971; Buffo and Rossi, 
2013).  
By E10 GN precursors of the mouse embryo begin to proliferate, then they acquire a unipolar 
morphology, with a single process that projects away from the rhombic lip.  
By E13 GN precursors exit the rhombic lip and migrate tangentially over the surface of the 
cerebellar primordium following a rostro-medial direction.  
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By E16 most of the cerebellar surface is covered by GN precursors, forming the EGL. The 
latter identifies a mitotically active region where GN precursors lose their processes, 
proliferate and then become post-mitotic, during the first two postnatal weeks (Altman, 
1972).   
The EGL can be divided in an outer layer (oEGL) containing mitotically-active 
p27Kip1-negative GNs progenitors and an inner layer (iEGL), in which p27Kip1-positive 
post-mitotic GNs start to differentiate and extend the bipolar processes of parallel fibers. 
Finally, GNs extend a third process perpendicular to the parallel fibers (PFs) and start to 
migrate radially along BG fibers to form the internal granule layer (IGL).  GN proliferation is 
promoted by the Sonic hedgehog (Shh) secreted from PCs (Ruiz i Altaba et al., 2002) 
(Figure 22). 
PFs form glutamatergic synapses with PC dendrites in the ML, while their dendrites 
in the IGL form synapses with muscoid fibers (MF). The EGL disappears by ~PN15 and both 
migration and maturation of GNs are complete by PN20 (Goldowitz and Hamre, 1998; 
Hatten, 1999).  
 
 
Figure 22. Granule neuron migration (Adapted from Ruiz i Altaba et al., 2002). 
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It has been suggested that BG also play a role in the migration of interneurons of 
ML (Buffo and Rossi, 2013).  
After being generated by the progenitors of the VZ, BS/SC continue to proliferate at the level 
of prospective white matter (PWM) (Hallonet and Le Douarin, 1993; Zhang and Goldman, 
1996a; Maricich and Herrup, 1999) and then, migrate radially and become progressively 
integrated in the expanding molecular layer (Yamanaka et al., 2004). Time-lapse video 
microscopy has revealed that the migration of BS/SC is very complex (Cameron et al., 2009). 
After entering the ML between PN6 and PN14, immature BC/SC exhibit a prolonged 
migration (∼53.7 h) that takes place in four radial and tangential phases (Figure 23) 
(Cameron et al., 2009):  
Phase I. BC/SC cross the PCL to enter in the upper ML. At this stage, they have a 
vertically-elongated soma and a single process orientated towards the pial surface. 
Once they reach the ML, they change orientation from vertical to horizontal; 
Phase II. Cells migrate tangentially in the upper ML, following a rostro-caudal 
direction. At the end of this phase the cells change orientation from horizontal to 
vertical with the single processes orientated toward the PCL; 
Phase III.  BC/SC migrate radially within the ML from the top to the bottom and vice 
versa at a reduced speed, repeatedly extending and withdrawing the leading 
processes. At the end of this stage the cells turn and change orientation from vertical 
to horizontal; 
Phase IV. Cells migrate tangentially in a rostro-caudal direction reaching their final 
destination, completely withdrawing the leading process and subsequently 
extending several dendrite-like processes in multiple directions that take contact 
with PCs and GCs.  
 
54 
 
 
 
Figure 23. Phases of basket/stellate cell migration in the ML of the developing 
cerebellum. Abbreviations: gcp, granule cell precursors; pmsbc, postmigratory stellate/basket cells; 
pmgc, postmigratory granule cells; BG, Bergmann glial cells; PC, Purkinje cells (Cameron et al., 2009).  
 
Accordingly, it has been proposed that migrating BC/SC follow different routes 
depending on the stage of migration. Probably, young interneurons follow BG fibers along 
their way from the white matter towards the EGL, while they follow bundles of ascending GN 
axons and PF to migrate within ML (Guijarro et al., 2006; Simat et al., 2007; Cameron et al., 
2009; Buffo and Rossi, 2013). It has been shown that BC axons along PC soma and 
dendrites are attracted by neurofascin 186 while SC axons and dendrites elongate following 
the BG scaffold under the guidance of Close Homologue of L1 (CHL1), that is expressed by 
BG and SCs during postnatal development (Ango et al., 2004; Ango et al., 2008).  
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2.5. The involvement of astrocytes and microglia in NP-C1 disease  
 
It has been shown that the NPC1 protein is expressed predominantly by astrocytic 
perisynaptic processes, playing a key role in the vesicular trafficking that is crucial for 
maintaining the structural/functional integrity of nerve terminals (Patel et al., 1999). 
Interestingly, in NP-C1 disease the terminal axonal and dendritic tree of neurons, closely 
associated with perisynaptic astrocytic processes, degenerate earlier than cell bodies (Patel 
et al., 1999). 
Both astrocytes and microglia are mediators of brain inflammation and the 
premature activation of these two cell types during the early stages of NP-C1 disease, 
suggests that inflammation plays an important role in the progression of this disorder (Baudry 
et al., 2003). In particular, reactive astrocytes are already observed nine days after birth in 
NPC1-KO animals (Reid et al., 2004). 
Astrocytosis has been also observed in PN120 Npc1nmf164 (Maue et al., 2012). 
However, these authors have not analyzed if this anomaly occurs at earlier disease stages 
neither the effect of CD treatment in rescuing this defect.  
Microglia plays a crucial role in the regulation of brain development and 
homeostasis, secreting several signaling molecules, such as cytokines, neurotransmitters 
and trophic factors (e.g. Brain derived neurotrophic factor, BDNF) that regulate 
neurogenesis, neuronal growth/survival, oligodendrogenesis, synaptic activity and functional 
plasticity (Tay et al., 2016).  
As part of innate immune system microglia detects external or internal danger signals and 
becomes active, thus eliminating pathogens by phagocytosis and releasing a variety of 
cytotoxic substances to protect CNS from inflammation and promote tissue 
repair/remodeling (Minghetti and Levi, 1998; Goldmann and Prinz, 2013).  
During development, activated microglia also phagocytes apoptotic neurons and 
mediates the synaptic pruning to increase the efficiency of neuronal transmissions (Marin-
Teva et al., 2004; Peri and Nusslein-Volhard, 2008; Paolicelli et al., 2011; Swinnen et al., 
2013).  
Although inflammation is a protective mechanism, the molecules produced and released by 
microglia during an inflammatory response, including glutamate, reactive oxygen species 
and nitric oxide are potentially cytotoxic.  
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Microglial activation appears from 2 weeks of age in Npc1 −/− mice in several 
regions, such as globus pallidus, ventral lateral thalamus, medial geniculate, cerebellum and 
DCN (Baudry et al., 2003). 
As for Npc1nmf164 mice, Maue and coll. (2012) have analyzed the microglia activation only in 
the cerebellum of PN120 mice, finding a high activation. However, it remains unclear, if in 
this murine model microglia activation also occurs at earlier stages of the disease.  
 
2.6. Oligodendrocyte differentiation: implication for NP-C1 disease 
 
After entering in the central mass of cerebellum, oligodendrocytes, gradually occupy 
both PWM and all cortical layers, then they undergo a typical maturation that parallels the 
spatio-temporal pattern of colonization of the cerebellum (Reynolds and Wilkin, 1988).  
The differentiation of oligodendrocytes is characterized by progressive 
morphological transformation. In the first differentiation step, oligodendrocyte precursor cells 
(OPCs) develop multiple immature processes (pro-oligodendrocytes). Then the pro-
oligodendrocytes become membrane sheath-bearing mature oligodendrocytes, and, finally, 
myelinating oligodendrocytes.  
Maturing oligodendrocytes express a typical sequence of marker, which reflects their 
progressive acquisition of mature traits. The OPCs highly express A2B5 antigen, platelet-
derived growth factor receptor-α (PDGFRα) and chondroitin sulphate proteoglycan (NG2) 
while the pro-oligodendrocytes O4. Mature oligodendrocytes are characterized by the 
expression of galactocerebroside (GC or O1 antigen) and 2′,3′-cyclic nucleotide 3′-
phosphodiesterase (CNPase), whereas myelinating oligodendrocytes express myelin 
proteins: myelin-associated glycoprotein (MAG), myelin basic protein (MBP) and proteolipid 
protein (PLP) (Zhang et al., 2011; Buffo and Rossi, 2013) (Figure 24).  
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Figure 24. Morphological changes and antigenic markers of developing 
oligodendrocytes (Zhang et al., 2011).  
 
Oligodendrocyte maturation is regulated by cell-autonomous mechanisms, cell-to-
cell interactions and diffusible factors (Chatonnet et al., 2001; Li et al., 2009; Emery, 2010a; 
Emery, 2010b).  
A critical role for oligodendrocyte development is played by thyroid hormones that 
at earliest stage of development indirectly influence oligodendrocytes 
proliferation/differentiation inducing the release of trophic factors from both PCs and 
astrocytes. In the adult life, thyroid hormones directly regulate the ability of the remaining 
precursors to divide or acquire mature traits (Fauquier et al., 2011; Picou et al., 2012). 
Evidence suggest that oligodendrocytes are required for neuronal maturation and 
the appropriate organization of the cerebellar cortex, acting by mechanisms not yet fully 
characterized (Mathis et al., 2003; Collin et al., 2007; Doretto et al., 2011).  
Indeed, the of ablation oligodendrocytes in mice at the third postnatal week causes a 
disorganization of the cortical layers and an abnormal foliation accompanied by decreased 
GN densities, altered development of PC dendritic tree, impaired migration of BC/SC 
interneurons and disorganized BG network (Mathis et al., 2003).   
The adult cerebellum is characterized by the presence of OPCs in the PWM and in 
both ML and GCL that maintain a proliferative activity and can differentiate in 
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oligodendrocytes for myelin remodeling throughout life and to repair myelin damage 
(Nishiyama et al., 2009; Young et al., 2013).  
However, in the adult cerebellum, OPCs express receptors for GABA and glutamate and 
respond to the gliotransmitter ATP that represents the functional substrate of neuron-
astrocyte interaction and promotes their differentiation (Wigley et al., 2007; Mangin and 
Gallo, 2011; Vèlez-Fort et al., 2012).  
It has been proposed that neurons regulate the rate of OPCs proliferation, 
maturation and migration (Gallo et al., 2008; Mangin and Gallo, 2011; Vèlez-Fort et al., 
2012). Each OPC of the ML receives about 70 input from a single CF, weaker inputs from 
PFs and is innervated by multiple olivary axons (Lin et al., 2005). Unlike synaptic contacts 
established by PCs, those established by OPCs are not enwrapped by BG (Lin et al., 2005). 
Although it was demonstrated that the glutamate release by CF causes the activation of 
calcium-permeable AMPA receptors on the surface of OPCs, the effect of this interaction for 
neuronal functioning remains unknown (Lin et al., 2005; Buffo and Rossi, 2013).  
Among the marker expressed by myelin and oligodendrocytes, in addition to 
proteolipid protein (PLP), myelin basic protein (MBP) represents the second most 
abundant protein in CNS myelin (about the 30%; Boggs, 2001; Baumann et al., 2001). 
Various MBP isoforms are generated by alternative splicing and exert specific functions in 
different intracellular compartments. Namely, the 17.2 and 21.5 kDa isoforms are highly 
expressed in the cell body and nucleus of developing oligodendrocytes, playing a regulatory 
role in the genetic program of oligodendrocyte differentiation (Pedraza et al., 1997). In 
contrast, the 18.5 kDa isoform localizes at the plasma membrane and actively participates 
in membrane compaction typical of mature myelin (Harauz and Boggs, 2013). 
Recently, it has been shown that the intracellular trafficking of lipids mediated by 
Npc1 is required for the formation and maintenance of CNS myelin. Indeed, the ablation of 
Npc1 in neurons impairs oligodendrocytes maturation and consequentially myelin formation.  
The ablation of Npc1 in oligodendrocytes causes a delayed myelination in the forebrain and 
corpus callosum of PN16 mice, whereas in adult mice causes the loss of myelin proteins 
which in turn leads to PC degeneration (Yu and Lieberman, 2013).  
This finding agrees with previous observations showing the expression of low-/very low-
density lipoprotein receptors by oligodendrocytes (Zhao et al., 2007) and the dependence 
on glia-derived cholesterol of Npc1-deficient brains (Borbon et al., 2012; Zhang et al., 2008).  
Moreover, dysmyelination and myelin loss were previously reported in prefrontal 
cortex, corpus callosum and hippocampus of Npc1−/− mice (Takikita et al., 2004) and found 
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to be associated with defective genetic control of oligodendrocyte differentiation (Yan et al., 
2011).  
In particular, MBP immunohistochemistry revealed that, starting from PN10 both the cerebral 
cortex and the corpus callosum of Npc1−/− mice display hypomyelination that becomes more 
evident at PN20 (Figure 25).  
MBP immunoreactivity remains preserved only in the deep layer of somatosensory cortex 
and cingulate cortex (Takikita et al., 2004). At PN20 Npc1−/− mice also display a 
hypomyelinated septum, whereas no difference was found in the optic chiasma in 
comparison to wt mice. The authors suggest that this deficit can be due to a failure of OPCs 
to myelinate axons or an axonal incapability to be myelinated (Takikita et al., 2004). 
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Figure 25. Distribution of myelin basic protein in PN10 (A, B), PN20 (C, D) and 
PN60 Npc1nih mice (E, F). Control mouse, left side (A, C, E); Npc1nih mouse, right side (B, 
D, F). MBP immunohistochemistry reveals obvious hypomyelination of cerebral cortex as 
well as corpus callosum in the Npc1nih mouse brain. Note that almost the entire cortex except 
the deep layer of somatosensory cortex and cingulate cortex is devoid of MBP 
immunoreactivity (D, F). Although relative hypomyelination is already recognized in 10-day-
old brain (PND10) (A, B), the difference of myelination becomes obvious in the mouse after 
PND 20. Comparing the images of PND20 and PND60, Npc1nih mice show no progress in 
myelination, whereas myelination extends towards pial surface in control mice (C–F). 
Similarity of cortical myelin distribution between PND60 Npc1nih mice brain (F) and PN10 
control brain (A) suggests that unmyelinated cortical area in PND60 Npc1nih mouse 
corresponds to the area of the late-onset myelination (Takikita et al., 2004).  
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Maue and coll. (2012) have used the diffusion tensor imaging (T2-weighted) by 
magnetic resonance imaging (MRI) to analyze myelination in Npc1nmf164 mice, finding no 
difference between Npc1nmf164 and wt mice for the T2 signal. The issue of whether also 
Npc1nmf164 display a deficit in the differentiation of oligodendrocytes and myelin maturation 
as well as if the myelination deficiency also affects the cerebellum was not investigated yet. 
 
 
2.7. Sonic hedgehog patterning during cerebellar development: 
implications for NP-C1 disease 
 
Sonic hedgehog (Shh) is a protein encoded by the SHH gene, which is part of the 
hedgehog (hh) family that also includes the Desert Hedgehog (Dhh) and the Indian 
Hedgehog (Ihh) proteins (Echelard et al., 1993).  
In mammalians, Shh is expressed from early embryogenesis and acts as morphogen, 
mitogen and guidance molecule for both cerebellar development and maturation (Fuccillo et 
al., 2006; Yam and Charron, 2013).  
Initially, Shh is synthetized as a 45 kDa precursor protein that is auto-proteolytically cleaved 
into a 19 kDa amino-terminus (Shh-N) with a signaling domain and a 26 kDa carboxy 
terminus (Shh-C) without signal transduction activity (Porter et al., 1996; Choen, 2004).  
Shh-N undergoes to a dual lipid modification, namely the covalent addition of cholesterol 
and palmitate, becoming an active signaling protein (De Luca et al., 2016).  
Shh is then trafficked to the cell surface and released from cells as a multimer (M-Shh-N) 
(Porter et al., 1996; Chamoun et al., 2001; Pipinsky et al., 1998).  
Shh signaling relies on primary cilium, a microtubule-based membrane cellular 
structure essential for signal reception and transduction (Goetz and Anderson, 2010) and 
on the binding to the transmembrane receptors Patched (Ptch). 
In the absence of Shh, Ptch represses Smoothened (Smo), a seven transmembrane G-
protein coupled receptor-like protein that represents the transducer of Shh signal inside the 
cell (De Luca et al., 2016).   
Upon Shh binding, Ptch relieves Smo inhibition, which in turn results in the activation of Gli 
family transcription factors and the activation of genes controlling cell proliferation and 
differentiation (Huangfu and Anderson, 2006; Ruiz i Altaba et al., 2007). 
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Besides the need of cholesterol for Shh activity per se, the downstream effectors of 
Shh signaling are cholesterol-dependent. In fact, Smo translocation to the cilium, which is 
necessary for its activation, is dependent on cholesterol availability (Karpen et al., 2001; 
Rohatgi et al., 2007).  
During the early embryonic life Shh is released by choroid plexus (ChP) and mediate 
the radial glial cell proliferation and the expansion of the progenitors of GABAergic neurons. 
Starting from E17.5, Shh is secreted by PCs and promotes the differentiation of radial glia 
in Bergmann glia. Postnatally, Shh supports the proliferation of both GNs and 
oligodendrocyte precursor (OPCs) cells in the EGL and PWM, respectively. In the PWM, 
Shh also promotes the proliferation of neural stem cell-like progenitors that generate both 
intermediate astrocyte precursors and GABAergic transient amplifying cells (De Luca et al., 
2016).  
At the end of the first post-natal week, PCs downregulate Shh expression and release 
vitronectin that induces oligodendrocyte maturation and myelin formation (Bouslama-
Oueghlani et al., 2012; Sotelo and Rossi, 2012) (Figure 25). 
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Figure 25. Shh functions during cerebellar development. (A) During the early embryonic life 
Shh is released by choroid plexus (ChP) and mediates the radial glial cell proliferation and the 
expansion of Ptf1a+ progenitors of GABAergic neurons. Starting from E17.5, Shh is secreated by 
Purkinje cells and promotes the differentiation of radial glia in Bergmann glia. (B). Postnatally, Shh 
supports the proliferation of both granule neurons and oligodendrocyte precursor cells (GCPs and 
OPCs), in the EGL and PWM, respectively. In the PWM, Shh also promotes the proliferation of neural 
stem cell-like progenitors (Tnc+CD133+) that generate both intermediate astrocyte precursors 
(Tnc+CD15+) and GABAergic transient amplifying cells (Ptf1a+). PCP Purkinje cell progenitor, ChP 
choroid plexus, PWM prospective white matter, GL granular layer, PCL Purkinje cell layer, EGL 
external granular layer (De Luca et al., 2016).  
 
Recently we have found that both Shh availability and signal reception at the levels 
of Patched receptor/Smoothened downstream effector is altered in NPC1 mice causing a 
defective GN proliferation (Nusca et al., 2014; Canterini et al., unpublished results).  
This finding suggests that oligodendrocyte and Bergmann glia differentiation, as well as the 
proliferation of neural stem cell-like progenitors, generating intermediate astrocyte 
precursors and GABAergic transient amplifying cells could be altered in NPC1 mice.  
 
2.8. The importance of BDNF signaling pathway in cerebellar 
development and current knowledge of its role in NP-C1 disease 
 
Brain-derived neurotrophic factor (BDNF) is a member of the nerve growth factor 
gene family and plays a crucial role in the development and maintenance of nervous system. 
In mice, the Bdnf gene consists of many non-coding exons (I, II, III, IV, V, VI, VII, VIII) 
followed by a single coding exon (IX), which encodes for the pre-pro-protein (pro-BDNF). 
Although the human gene is very similar, it differs for additional exons V and VIII and for a 
more complex pattern of alternative splicing involving the exon IX (Koppel et al., 2009) 
(Figure 26).  
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Figure 26. Schematic drawings of rodent and human BDNF genes. (A) Rodent BDNF gene 
(B) Human BDNF gene (C) Representation of untranslated (white square) and coding sequence (black 
square) (adapted from Koppel et al., 2009). 
 
Once the pro-BDNF is translated, it is converted by the enzyme furin into mature 
BDNF and directly released exerting its function by binding the tropomyosin receptor kinase 
B (TrkB). Alternatively, it can be converted into a mature form by proconvertase enzymes 
and stored in secretory vesicles. Furthermore, cells can directly release unprocessed pro-
BDNF. In this case, pro-BDNF can be either converted into mature-BDNF by plasmin or 
function as a signal molecule per se by binding p75NTR receptor (Barker, 2009) (Figure 27).  
 
 
Figure 27. BDNF production and processing in the central nervous system (Adapted 
from Barker, 2009).  
 
The binding of pro-BDNF to p75NTR receptors promotes both apoptosis and cell 
survival, by the c-Jun N-terminal kinase (JNK) and nuclear factor kappa-light-chain-
enhancer of activated B cell (NF-Kb) signaling cascade, respectively. Instead, the binding of 
BDNF to TrkB receptors leads to the activation of three main signaling pathways: 1) 
Phospholipase C (PLC); 2) Phosphoinositide 3-kinase (PI3K); and, 3) extracellular signal–
regulated kinase (ERK). These three pathways finally lead to the activation of CREB 
transcription factor that mediates the transcription of genes essential for both neuronal 
survival and differentiation (Cunha et al., 2010).  
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 Among signaling pathways controlling cerebellar development, mature-BDNF acts 
as a chemiokinetic factor to induce GN migration and as chemiodinamic factor to guide GNs 
along BGs fibers (Borghesani et al., 2002).  
Furthermore, BDNF is required for the development of dendritic spines and arborizations of 
PCs and axonal growth of GNs, to modulate the dendritic morphology of BCs/SCs and to 
regulate the cholesterol metabolism for synapses formation (Suzuki et al., 2007a,b; Mertz et 
al., 2000).  
However, during neurodevelopment pro-BDNF mediates opposite effects compared to 
BNDF, by promoting apoptosis and negatively regulating neurite growth, dendritic spine 
formation and GN migration (Nagappan and Lu, 2005; Khoshimizu et al., 2009; Xu et al., 
2011).  
In fact, it has been shown that BDNF-/- mice display a defective foliation and 
development of PC dendritic tree, as well as a reduced thickness of ML, an increased death 
of proliferating cerebellar neurons and developed ataxia (Schwartz et al., 1997). Instead, 
TrkB deficient-mice display a multiple CF innervation of a single PC, a reduced thickness of 
both ML and GCL, altered GABA synthesis and uptake and altered formation and maturation 
of GABAergic synapses (Rico et al., 2002).   
Besides, BDNF elicits neuronal de novo synthesis of cholesterol stimulating the 
transcription of several enzymes involved in the cholesterol biosynthetic pathway (Suzuki et 
al., 2007a,b). The BDNF-dependent cholesterol biosynthesis plays a critical role for the 
development of synapses and lipid rafts (Suzuki et al., 2007a,b).  
It has been shown that defective cholesterol metabolism of embryonic striatal 
neurons of Npc1-/- mice is associated with a defective neurite outgrowth due to the BDNF 
failure to activate TrkB receptors (Henderson et al., 2000). It was also reported that neural 
stem cells of Npc1-/-  mice show an impaired self-renewal and differentiation, due to the 
imbalance between histone deacetylase (HDAC) and histone acetyltransferase (HAT) 
activities, resulting in the down-regulation of the expression of Bdnf and TRKB genes (Kim 
et al., 2007).  
In spite of this evidence, the issue of whether the BDNF signaling pathway in the 
developing cerebellum of Npc1-deficient mice has not yet been investigated.  
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Chapter III 
 
The research project 
 
 
3.1. Background and aims  
 
 We have recently shown that in Npc1-/- mice there is an overall cerebellar size 
and external granule layer (EGL) thickness reduction, due to a deficit of the proliferation of 
granule neuron (GN). This leads to a deficiency of GNs in the Inner Granular Layer (IGL), 
which may contribute to the later Purkinje cell (PC) degeneration (Nusca et al., 2014).  
 In line with the robust mitogenic activity Sonic Hedgehog (Shh) exerts on GNs 
(Wechsler-Reya and Scott, 1999), Shh mRNA levels were found to be significantly reduced 
in both Npc1-/- and Npc1nmf164 mice at the time of final divisions of GN precursors (Nusca et 
al., 2014; Canterini et al., manuscript in preparation). Thus, the reduced Shh availability may 
cause a GN proliferation deficit in both mouse models.  
 Among the animal models of NP-C1 disease, the Npc1nmf164 mouse is of particular 
interest because it harbors a single nucleotide substitution (A to G at cDNA bp 3163) causing 
an aspartate-to-glycine substitution (D1005G) in the cysteine-rich luminal loop, conferring to 
the NPC1 protein a partial loss of activity as observed in most common human mutations 
(Maue et al., 2012).  
 Besides GNs, also Bergmann glia (BG) responds to Shh (Corrales et al., 2004) 
by differentiating along with PC maturation, especially promoting PC dendritic tree extension 
and enwrapping the GABAergic and glutamatergic synaptic contacts that PCs receive from 
Basket/Stellate interneurons (BCs/SCs) and parallel/climbing fibers, respectively (Yamada 
and Watanabe, 2002). This suggests that Npc1-deficiency also affects the normal pattern of 
both BG differentiation and functionality.  
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 Shh is required for oligodendrocyte precursors (OPCs) generation and 
subsequent differentiation into mature oligodendrocytes (Nery et al., 2001). Although 
previous studies have shown dysmyelination in both NPC patients and Npc1−/− mice 
(Takikita et al., 2004; Walterflang et al., 2010), the effect of Npc1-deficiency on 
oligodendrocyte differentiation has not been well characterized in the cerebellum.  
 Previous studies have reported that in Npc1-/- mice there is an increased number 
of reactive astrocytes (astrocytosis) starting from nine days after birth in thalamus and cortex 
(Reid et al., 2004), whereas in Npc1nmf164 the presence of astrocytosis was analyzed and 
found only in the adult cerebellum (Maue et al., 2012).  
Also, the presence of microglia activation was only investigated in adult Npc1nmf164 mice. 
 Besides Shh, also the Brain-Derived Neurotrophic Factor (BDNF) exerts a crucial 
role for proper proliferation and differentiation of various neuronal and glial cells, likely 
influencing the overall pattern of synaptic connectivity of the cerebellar cortex.  
Mature-BDNF is synthesized from the pro-BDNF but both proteins acts as signaling 
molecules by binding the TrkB and p75NTR receptors, respectively (Barker, 2009). 
However, during the neurodevelopment pro-BDNF mediates opposite effects compared to 
BNDF, by promoting apoptosis and negatively regulating neurite growth, dendritic spine 
formation and GN migration. In light of the finding that, BDNF expression is regulated by Shh 
through post-transcriptional mechanisms (Bond et al., 2013), we have hypothesized that 
BDNF signaling might be altered in Npc1nmf164 mice.  
 Evidence so far obtained prompted us to further investigate above mentioned 
issues, by addressing the following aims: i) to characterize whether the altered Shh signaling 
pathway influences Bergmann glia, oligodendrocyte and Purkinje cell differentiation; ii) to 
characterize the BDNF signaling; iii) to analyze astrocytes/microglia activation and microglia 
mediated-phagocytosis in the early stage of cerebellar development.  
In light of the efficacy of 2-hydroxypropyl-β-cyclodextrin (CD) in rescuing cerebellar 
anomalies of mouse models (e.g. see paragraph 1.9), these issues were investigated in 
Npc1-deficient mice either treated or untreated with CD. 
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3.2. Materials and methods  
 
3.2.1. Mice 
Npc1nmf164/nmf164 mice with BALB/cJ background (hereafter named Npc1nmf164 mice) 
were generated by heterozygous crosses and maintained in our animal facility in accordance 
with Sapienza University guidelines for the care and use of laboratory animals. Experimental 
protocols and related procedures were approved by the Italian Ministry of Public Health. All 
efforts were made to minimize animal suffering, according to European Directive 
2010/63/EU.  
3.2.2. Genotyping  
Genotypes were identified by PCR analysis accordingly to Maue et al., (2012). 
Genomic DNA was extracted from tail biopsy using the HotShot method (Truett et al., 2000).  
~1ul of DNA was used for to generate a 176 bp PCR product using the following primer pairs 
and conditions: 
- Reverse primer: 5’-AGGACCCTTCCGTACAAGC-3’ 
- Forward primer: 5’-GGCCTCCAGGGGAAAGAATT-3’ 
 
 
 
Cycle step Temperature Time 
Number of 
Cycles 
Pre-denaturation 95 °C 
 
1 min 
 
1 
Denaturation 
Annealing 
Extension 
95 °C 
62 °C 
73 °C 
16 sec 
16 sec 
15 sec 
 
 
 
 
38 
Final extension 
Hold 
72 °C 
12 °C 
3 min 
5 min 
1 
1 
 
To discriminate the single base change (A to G) PCR product was then incubated 
at 37 °C for 1 h with the restriction enzyme BstEII that generates two fragments of 128 and 
48 bp in the presence of the G allele. 
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3.2.3. Treatments  
 
The treatment schedule was the following: both Npc1nmf164 and wt pups received two 
consecutive subcutaneous injections at PN4 and PN7 of 2-hydroxypropyl-β-cyclodextrin in 
PBS (hereafter named CD; average degree of substitution of 0.67 of hydroxypropyl groups 
per glucose unit, MW ~1369 Da, catalog number H-107, Sigma Aldrich, Milan, Italy) (w/v; 
4000 mg/Kg body weight) (Palladino et al., 2015). Age-matched control mice received plain 
PBS injections (sham animals).  
For CD/sham administration, pre-weaning pups were separated from the mother, 
weighed, injected at the scruff of the neck (Liu et al., 2008), monitored for complete 
absorption of the injection bolus and finally returned to the home cage. The entire injection 
procedure lasted approximately 15–20 min, giving each pup a similar treatment, inclusive of 
maternal separation, handling and injection.  
 
3.2.4. Western blot assays 
 
For Western blot analyses, total proteins of PN11 and PN15 Npc1nmf164 and wt 
littermates cerebella (4 mice/genotype/age) were extracted with RIPA buffer (Sigma Aldrich, 
Milan, Italy) supplemented with protease and phosphatase inhibitors (Roche Life Science, 
Indianopolis, IN, USA). The protein concentration was routinely determined by Bradford’s 
colorimetric assay (Bio-Rad, Milan, IT).  
Equal amounts of total protein/lane were fractionated by electrophoresis on a 4–
12% gradient SDS-polyacrylamide gel (Bolt® Bis-Tris Plus gels, Life Technologies, 
Carlsbad, CA, USA) or 10 % gel pre-cast (Bio-Rad). Fractionated proteins were transferred 
to PVDF membranes (GE Healthcare, Little Chalfont, UK) and then processed for Western 
blot analyses.  
When proteins of interest had very different electrophoretic migrations, such as in 
the case of Glutamine synthetase and MBP, membranes were cut into strips to be probed 
with different antibodies. The primary and secondary antibodies used are reported in Table 
1.  
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Table 1. Antibodies used 
Antibody Company 
Dilution 
WBa IHCa 
P
ri
m
a
ry
 
anti-GFAP 
Santa Cruz Biotechnology, Santa Cruz, CA, 
USA; #sc-33673 
1:500 1:50 
anti-EAAT1 or GLAST AbCam, Cambridge, UK; #ab416 1:1500 1:250 
anti-Glutamine Synthetase AbCam; #ab73593 1:2000 1:333 
anti-VGluT2 
Thermo Fisher Scientific, Rockford, IL; USA; 
#PA5-25653 
1:1000 1:50 
anti-GAD65 AbCam; #ab26113 1:2000 1:200 
anti-MBP 
Sigma-Aldrich Inc., St. Louis, MO, USA; 
#M3821 
1:500 1:100 
anti-p27Kip1 Epitomics, Burlingame, CA, USA; #P46414 ----- 1:75 
anti-parvalbumin  Sigma-Aldrich Inc., #P2088 ----- 1:700 
anti-CD11b AbCam; #ab133357 1:1000 ----- 
anti-CD68 Santa Cruz Biotechnology; #sc-59103 1:100 ----- 
anti-BDNF Santa Cruz Biotechnology; #sc-546 1:250 ----- 
anti-p75NTR Santa Cruz Biotechnology; #sc-271708 1:1000 ----- 
anti-TrkB Santa Cruz Biotechnology; #sc-377218 1:1000 ----- 
Anti-BrdU Immunological science, Milan, Italy; #IK-11143 ----- 1:100 
anti-β-actin AbCam; #ab6276 1:1000 ----- 
S
e
c
o
n
d
a
ry
 
Horseradish peroxidase-conjugated 
goat anti-rabbit IgG 
Thermo Fisher Scientific; #32460 1:200 ----- 
Horseradish peroxidase-conjugated 
goat anti-mouse IgG 
Thermo Fisher Scientific; #32430 1:650 ----- 
Horseradish peroxidase-conjugated 
goat anti-mouse IgG2a 
Santa Cruz Biotechnology; #sc-2061 1:3000 ----- 
Biotinylated goat anti-rabbit IgG 
Vector Laboratories, Burlingame, CA; #PK-
6101 
----- 1:200 
Biotinylated goat anti-mouse IgG Vector Laboratories; #PK-6102 ----- 1:200 
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3.2.5. Brain collection and sectioning  
 
PN11 and PN15 Npc1nmf164 and wt littermates untreated, sham- or CD-treated (4 
mice/genotype) were deeply anaesthetized by intraperitoneal injection of a mixture of 
xylazine (20 mg/Kg) and ketamine (34 mg/Kg) and then transcranially perfused with 4% PFA 
in 0.1 M PBS. Brains were removed and post-fixed overnight at 4 °C in 4 % PFA. PFA-fixed 
brains were dehydrated, embedded in Paraplast Tissue Embedding Medium (Leica 
Biosystems, Milan, Italy) and serially sectioned (slice thickness 8 μm). 
Sagittal sections were mounted on X-tra Adhesive glass slides (Leica Biosystems), de-
waxed with xylene, rehydrated and washed in PBS. 
Alternatively, the detection of some markers was performed on cryosections. For 
this reason, PFA-fixed brains were cryoprotected with sucrose (30 %, w/v, in PBS), 
embedded in FSC22 Clear R Frozen Section Compound (Leica Biosystems) and sagittally 
sectioned (slice thickness 8 μm) using a Leica CM 1900 cryostat. Sections were mounted 
on X-tra Adhesive glass slides (Leica Biosystems) and washed in PBS. 
 
3.2.6. Immunohistochemistry 
 
For p27kip1 immunostaining rehydrated paraffin sections of PN15 wt, Npc1nmf164 and 
Npc1nmf164 CD-treated mice were incubated (5 minx2) in 10 mM sodium citrate, pH 6.0 in a 
microwave for epitope unmasking. Hence, sections were incubated first with Trypsin working 
solution (0,05% trypsin, 0,1% calcium chloride in dH20) for 15 minutes at room temperature 
(RT) and then with 2M HCl for 20 minutes to permeabilize tissue. To inactivate endogenous 
peroxidase, sections were incubated in 5% hydrogen peroxide for 15 minutes and then 
subjected to a blocking/permeabilization (30 min incubation in a buffer containing 6% goat 
serum and 0,3% Triton X-100 in PBS). Incubation with rabbit monoclonal primary antibody 
against p27kip1 was carried out overnight at 4°C. After 3 washes in PBS, sections were 
stained using first the rabbit Vectastain Elite ABC Kit (Vector Laboratories Inc., Burlingame, 
CA, USA), allowing specific ABC complex development, and then the DAB Peroxidase 
Substrate Kit (Vector Laboratories Inc., Burlingame, CA, USA) acc. to the protocol supplied 
by the manufacturer. Nuclear counterstaining was performed by incubating sections with 
0,5% Methyl Green solution (0,5% Methyl Green, 0,1M sodium acetate buffer in water, ph 
4.2) for 5 minutes at 60°C. After dehydration, slices were mounted with Eukitt mounting 
medium (Electron Microscopy Sciences, Hatfield, PA, USA). 
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For parvalbumin immunostaining, rehydrated paraffin sections of PN15 wt and 
Npc1nmf164 were subjected to a blocking/permeabilization step consisting in a 30 min 
incubation in PBS supplemented with 5% normal goat serum, 0.3% Triton X-100. Sections 
were then incubated with a monoclonal antibody directed to parvalbumin, supplemented with 
3% normal goat serum, overnight at 4°C, washed 3-4 times with PBS and stained using the 
mouse Vectastain Elite ABC kit and the DAB peroxidase substrate kit (Vector Laboratories 
Inc., Burlingame, CA, USA) according to the protocol supplied by the manufacturer. After 
dehydration, slices were mounted with Eukitt mounting medium (Electron Microscopy 
Sciences, Hatfield, PA, USA). The number of PCs and basket/stellate interneurons was 
determined in 0.04 mm2 regions randomly selected in each field of anterior (I-V) and 
posterior (VI-X) lobules of wt and Npc1nmf164 mice (N = 3 mice/genotype; 3–4 
sections/mouse) using the function “cell counter” of ImageJ NIH software. Histological 
observations/evaluations were blindly and independently performed by two investigators. 
MBP immunostaining was carried out using rehydrated paraffin sections while the 
detection of other glial and neuronal cell markers (GLAST, GFAP, Glutamine synthetase, 
VGluT2 and GAD65) was performed on cryosections of PN15 wt and Npc1nmf164 mice, 
untreated, sham- or CD-treated.  
For GLAST detection, cryosections were subjected to 20 min fixation in acetone (−20 °C), 
which significantly improved antigen detection (Finckbone et al., 2009). Paraffin sections 
and cryosections were then processed for epitope unmasking and endogenous peroxidases 
inactivation.  
For antigen unmasking, sections were incubated (5 min x 2) in 10 mM sodium citrate, pH 
6.0 in a microwave and then incubated in 0.3% H2O2 for 15 min at RT to inactivate 
endogenous peroxidases. A 2 h incubation in a blocking solution made of 0.5 % BSA in PBS 
preceded the incubation of sections with anti-GLAST and anti-MBP antibodies.  
For the detection of VGlut2, GFAP, Glutamine synthetase and GAD65 the blocking solution 
was supplemented with 0.1% Triton X-100. The incubation of sections with primary 
antibodies lasted approximately 18 h at 4 °C and was followed by several washes in PBS 
before exposure to the appropriate secondary antibody (see Table 1 for details).  
Antibody-antigen complexes were revealed with Vectastain Elite ABC Kit (Vector 
Laboratories Inc., Burlingame, CA, USA) followed by DAB Peroxidase Substrate Kit (Vector 
Laboratories Inc.), according to manufacturer’s instructions.  
After dehydration, slices were mounted with Eukitt mounting medium (Electron 
Microscopy Sciences, Hatfield, PA, USA). Images were obtained using a Zeiss Axioplan 
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microscope equipped with a Sony nex-3 N mirror-less camera (Sony Europe Limited, Milano, 
Italy) and processed using ImageJ NIH software (National Institutes of Health, Bethesda, 
MD).  
VGluT2- and GAD65-positive puncta were quantitated in 3–4 sagittal sections of 4 
mice/genotype as previously described (Grimes et al., 2003; Lin et al., 2014) with slight 
modifications. 
Images were acquired using a Zeiss Axioplan microscope at 100X magnification 
(Neofluar, 0.7–1.30) and a Sony nex-3 N mirror-less camera. For each antibody, at least 8 
image fields of lobule II and lobule X were acquired along the molecular layer starting from 
the pial surface.  
The abundance of VGluT2- and GAD65-positive puncta was determined in regions 
of interest (ROI) of 6500 μm2 and 3200 μm2, respectively, randomly selected in outer and 
inner molecular layers by the “cell counter” function of ImageJ NIH software. The number of 
GAD65-positive puncta around the PC’s soma was also determined. Only VGluT2- and 
GAD65-positive puncta having a high-to-moderate staining and a diameter of 0.3–1.3 μm 
were counted. All determinations were performed blindly and independently by two 
investigators.  
Because no significant difference was observed between counts of lobule II and lobule X 
microscopic fields of wt or Npc1nmf164 mice, data were pooled. 
To assess GN proliferation, brains were dissected from PN13 and PN15 wt, 
Npc1nmf164 and Npc1nmf164 CD-treated mice that had received a single BrdU injection 20 h 
before and processed as previously described (Nusca et al., 2014). Briefly, epitopes were 
unmasked by heating sections 2 × 5 min in 10 mM sodium citrate, pH 6.0, in a microwave 
oven and tissue permeabilization was achieved by incubation in trypsin solution (0.05% 
trypsin, 0.1% CaCl2 in water) for 15 min at room temperature (RT) and then in 2 M HCl for 
30 min. Histological sections were then incubated overnight at 4 °C with a monoclonal anti-
BrdU antibody in PBS supplemented with 0.5% Tween 20, and then for 45 min with an anti-
mouse IgG antibody (Alexa Fluor-555 InVitrogen, Milan, Italy; 1:1500 final dilution). After 
counterstaining with 0.5 μg/mL Hoechst (Hoechst-33258, Invitrogen, Milan, Italy) for 4 min, 
sections were mounted with Prolong Gold Antifade Reagent and analyzed with an 
epifluorescence Zeiss microscope.  
For quantification of BrdU-immunopositive cells, regions of interest were randomly selected 
from bases and crowns of the anterior (I-V) and posterior (VI-X) lobules of 4 cerebella for 
each developmental stage. The total number of cells was determining in 100 μm2 regions 
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based on Hoechst staining (4 mice/genotype; 3–4 sections/mouse) as described for 
parvalbumin immunostaining. 
 
3.2.7. Histological analyses  
 
The overall cerebellar size was determined by using rehydrated paraffin sections of 
PN15 wt, Npc1nmf164 and Npc1nmf164 CD-treated mice. Sections were incubated with 
hematoxylin (Sigma-Aldrich, Milan, Italy) for 15 min and then washed in running hot water 
for 15 min. After a brief washing in dH20, sections were immersed in 95% ethanol for 30 s 
and then incubated with eosin Y (0.3% in ethanol 80%; Sigma-Aldrich) for 15 sec. Sections 
were dehydrated and mounted with Eukitt mounting medium (Electron Microscopy Sciences, 
Hatfield, PA, USA). Images were obtained using a Zeiss Axioplan microscope equipped with 
a Sony nex-3 N mirror-less camera (Sony Europe Limited, Milano, Italy).  
The area of total cerebellum volume, was independently measured by two 
investigators on three consecutive mid-sagittal sections of at least five mice per group, using 
ImageJ NIH software version 1.47v (National Institutes of Health, Bethesda, MD). Images to 
be compared were carefully selected paying attention that they were the closest possible to 
the parasagittal position, as inferred by the deeper white matter tracts matching very well in 
each image. The region of interest (ROI) in each section was outlined using the “selection 
brush” or the “polygon tool”, obtaining similar results.  
The number of BG, PC and Basket/Stellate interneurons was determined as 
previously described for parvalbumin immunostaining.  
To determine the number of GNs, rehydrated paraffin sections of PN15 wt, 
Npc1nmf164 and Npc1nmf164 CD-treated mice were stained with 0.5 μg/mL Hoechst (Hoechst-
33258, Invitrogen, Milan, Italy) for 4 min.  
Sections were mounted with Prolong Gold Antifade Reagent and analyzed with an 
epifluorescence Zeiss microscope. The total number of cells was determined in 100 μm2 
regions (4 mice/genotype; 3–4 sections/mouse).  
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3.2.8. Behavioral assessment 
 
Preweaning and adult behavioral performances were analyzed on the same cohorts 
of 10 Npc1nmf164 and 10 wt littermates, obtained from 5 litters made of at least 7 pups. 
Because a preliminary evaluation ruled out any gender effect on preweaning and adult 
behavioral performances, male and female mice were grouped together for analyses.  
The effect of CD administration on behavioral performances of preweaning pups 
was assessed on a cohort of 10 Npc1nmf164 and 10 wt littermates (5 pups either PBS- or CD-
injected/genotype), obtained from 5 litters made of at least 7 pups. 
Preweaning behavior assessment 
From postnatal day (PN) 3 to PN21, pups were separated from their dams daily 
between 9:00 a.m. and 3:00 p.m. for a maximum of 15 min, and tested for physical, postural, 
locomotor and complex motor behavior development in a warmed environment (30–32 °C) 
(Petrosini et al., 1990; Caporali et al., 2014). Behavioral assessment evaluated the 
development of physical parameters (body weight, eye opening, fur appearance, incisor 
eruption), locomotion (pivoting, crawling, quadrupedal locomotion), swimming performance 
(direction and limb use), reflex appearance (surface righting reflex, negative geotaxis, cliff 
avoidance) and complex motor behaviors (ascending a ladder, crossing a narrow bridge, 
suspension on a wire). Besides direct behavioral observations, videos were also recorded 
throughout the entire test cycle. To avoid the possibility of order effect(s), the test sequence 
was administered to each pup in random order for each test. The attribution of the dominant 
behavior to a specific category in each observation period was made blindly with regard to 
pup’s genotype. Categorization was considered reliable only when judgments were 
consistent (inter-rater reliability > 0.9). The test batteries used for the assessment of physical 
and sensorimotor development were as follows: 
(a) Physical development. The body weight was measured daily in the interval PN3-PN21 
and eye opening, fur appearance and incisor eruption were evaluated by visual inspection. 
(b) Development of quadrupedal locomotion. Fluent forward movements with all limbs 
supporting the whole body and the pelvis elevated were analyzed from PN3 to PN15 by 
using Ethovision XT software (Noldus, The Netherlands). The pup was placed on a board 
and video-recorded for 120 s to analyze the following locomotion categories: (i) pivoting, 
turning movements by broad swipes with forepaws, using only one hindlimb as a pivot and 
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having the pelvis anchored to the ground; (ii) crawling, dragging the body forward or pushing 
it backward by undulating movements of the trunk and often dragging the hindlimbs in an 
extended position with foot soles facing upward; (iii) quadrupedal locomotion, smooth and 
coordinated walking, in which the body is supported in sequence by different numbers of 
feet in combination, suitable for variegated velocities and without any directional bias. The 
developmental acquisition of the various locomotion categories was determined as dominant 
behavior according to the rating scale of Table 2. 
  
 
Table 2. Rating scale of the development of quadrupedal locomotion and swimming 
performance.  
 
(c) Development of swimming performance. The pup was gently released in a glass tank 
(cm 100 × 50 × 20) filled with warmed (35 °C) water and allowed to swim freely. The 
parameters swimming direction and limb use were evaluated and scored according to the 
rating scale of Table 2. 
 (d) Reflex appearance. (i) Surface righting reflex: the pup was placed gently on its back 
and the time to turn over on the belly was recorded (allotted time 30 s). (ii) Negative geotaxis: 
the pup was placed on an inclined (30°) plane with the head pointing downwards and the 
time to face up to the slope was recorded (allotted time 60 s). (iii) Cliff avoidance: the pup 
was placed on an edge with forepaws and nose just over the edge and the time to retract 
itself by backward and/or sideward movements was recorded (allotted time 60 s). 
(e) Development of complex motor behaviors. Because the acquisition of complex motor 
abilities requires the complete maturation of basic reflexes such as the grasping response, 
which normally appears by the end of the first postnatal week (Heyser, 2004) the 
development of complex motor behaviors was scored from PN10 on: 
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(i) Ascending a ladder: the pup was placed on a steel ladder (cm 15 × 25, 20 rungs, 1 cm 
apart, inclination angle 25°) with top leaning against a platform holding littermates. The ability 
to ascend the ladder within 120 s was evaluated and the day of the first successful 
performance was recorded; 
(ii) Crossing a narrow bridge: the pup was placed on the start platform connected by a 
plywood bridge (40 × 1 × 3 cm) to the goal platform holding littermates. The ability to traverse 
the bridge within 120 s was evaluated and the day of the first successful crossing was 
recorded; 
(iii) Suspension on a wire: the pup was suspended by its forepaws on a wire (2 mm diameter 
and 50 cm long) extended horizontally between two poles (30 cm high). The suspension 
time and the first suspension with the 4 limbs (hind limb suspension) were recorded (allotted 
time 60 s).  
Adult behaviour assessment 
PN30, PN60 and PN90 Npc1nmf164 and wt littermates were subjected to two daily 
sessions (morning and afternoon) of the following consecutively administered tests 
assessing motor behavior (Võikar, 2002): 
(i). Vertical screen: the mouse was placed on a horizontal wire screen (cm 15x25, wire 
diameter 2 mm, spaced at 1 cm). The screen was rapidly turned to vertical position with the 
mouse facing the floor at the lower edge. The latency to turn upward and to climb to the 
upper edge was measured during 60 s. This test was performed as the first one of the 
morning session and was not repeated in the afternoon of that day; 
(ii). Balance beam: the mouse was placed perpendicularly at the center of a horizontal round 
beam (covered with paper tape, outer diameter 2 cm, length 1 m, divided into 10 sections 
and placed 50 cm above a padded surface). The retention time and the number of beam 
sections crossed during 180 s were recorded and the results of morning and after- noon 
trials were averaged;  
(iii). Coat hanger: the mouse was suspended in the middle of the horizontal bar of a coat 
hanger (diameter 3 mm, length 35 cm, placed 30 cm above a padded surface) with its 
forepaws. The body position of the animal was observed for 60 s and scored as follows: 0, 
a fall within 10 s; 1, grasping the hanger with one limb; 2, grasping the hanger with two limbs; 
3, grasping the hanger with three limbs; 4, grasping the hanger with four limbs; 5, actively 
escaping to the end of the bar. The values of morning and afternoon trials were averaged. 
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These tests were selected because they were similar to those we had exploited in behavioral 
analyses of preweaning pups in terms of functions evaluated and experimental setting.  
 
3.3. Statistical analyses 
 
Statistical analyses were performed with STATISTICA 8 (StatSoft) software. Data 
were first tested for normality (Wilk-Shapiro’s test) and homoscedasticity (Levene’s test), 
and then analyzed by unpaired two-tailed Student’s t test or two-way ANOVAs for 
independent (genotype, treatment) and repeated (age) measures, followed by Bonferroni’s 
post-hoc test. When data did not fully meet parametric assumptions, or were ordinal 
(locomotion and swimming measures), comparisons between groups were performed by 
Mann-Whitney’s U test.  
To control for alpha inflation, i.e. the proportion of type I errors among all rejected 
null hypotheses, the False Discovery Rate (FDR) was set to 0.05 and estimated through a 
bootstrap procedure (Storey, 2004). Differences were considered to be significant at the p ≤ 
0.01 level.  
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3.4. Results 
 
3.4.1. The overall cerebellar size is reduced in Npc1nmf164 and is rescued 
by CD treatment  
 
The size of the adult cerebellum mainly depends on granule neuron (GN) 
proliferation in the external granule layer (EGL) (Solecki et al., 2001).  
In the mouse, GN proliferation lasts from embryonal day E18.5 up to PN16.5 and is regulated 
by the release of Sonic hedgehog (Shh) by Purkinje cells (PCs), which thereby determines 
both final cerebellar size and shape (Vaillant and Monard, 2009; Wallace, 1999; Wechsler-
Reya and Scott, 1999).  
Because of the covalent attachment of a cholesterol moiety to the C-terminus of the 
proteolytically-generated active Shh fragment (Repetto et al., 1990; Lanoue et al., 1997; 
Dehart et al., 1997), we hypothesized that impaired cholesterol availability associated to 
Npc1-deficiency might influence GN proliferation.  
To address this issue, we measured the total cerebellar area of hematoxylin/eosin 
Y stained parasagittal sections of PN15 wt, Npc1nmf164 and Npc1nmf164 CD-treated mice.  
This analysis showed that, similarly to Npc1-/- mice (Nusca et al., 2014), also Npc1nmf164 mice 
display a 25-30% reduction in cerebellar size in comparison to wild-type (wt) age-matched 
mice.  
Two consecutive subcutaneous injections of 2-hydroxypropyl-β-cyclodextrin (CD) to 
PN4 and PN7, largely rescues this phenotype (Figure 1). 
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Figure 1. Cerebellum of PN15 Npc1nmf164 mice is reduced in size.  (A) Hematoxilin/eosin Y 
stain of sagittal sections of cerebellar vermis of PN15 wt, Npc1nmf164 and Npc1nmf164 CD-treated mice. 
Representative sections encompassing sagittal midline of vermis are shown in the figure. 
Superimposition of total vermis tracings indicates an overall size reduction in Npc1nmf164 compared to 
wt mice that was largely rescued by CD treatment. Scale bars indicate 500 m. (B) Histograms indicate 
total areas (mean ± SEM; 3 mice/group) measured on representative sections of Npc1nmf164 (empty 
bar), Npc1nmf164 (full bar) and Npc1nmf164   CD-treated mice (dashed bar). Asterisk indicates statistically 
significant differences (unpaired two-tailed Student’s t test, *p < 0.05). 
 
 
wt 
Npc1nmf164 
Npc1nmf164 
CD 
A 
B 
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3.4.2. Npc1nmf164 mice display a reduced density of GNs in the external 
granule layer (EGL) 
 
Since the time of birth, some GN precursors exit the cell cycle and begin to 
differentiate into mature GNs (Altman and Bayer, 1996).  
Then, post-mitotic GNs migrate along Bergmann glia (BG) fibers and cross both molecular 
layer (ML) and Purkinje cell layer (PCL) to form the Internal granule layer (IGL) (Buffo and 
Rossi, 2013). This leads to the gradual thinning and disappearance of the EGL by the third 
post-natal week (Altman and Bayer, 1996). 
We determined the EGL thickness in parasagittal sections obtained from cerebella 
of PN15 wt, Npc1nmf164 and Npc1nmf164 CD-treated mice. The EGL was visualized by staining 
GN nuclei with Hoechst-33258, while GN density was determined by counting cell nuclei in 
randomly selected regions of 100 m2 each.This analysis showed that the EGL thickness 
and GN densities of Npc1nm164 mice were significantly reduced compared to wt mice. Indeed, 
only few scattered GNs, not even forming a single row of cells, were observed in both crowns 
than fissures of anterior and posterior lobules of Npc1nmf164 mice.  
Two consecutive subcutaneous injections of CD performed at PN4 and PN7 doubled 
the number of GNs in the EGL of PN15 Npc1nm164 mice, leading to a neuronal population 
even greater than that of wt mice (Figure 2A,B). 
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Figure 2. Npc1nmf164 mice display a reduced granule cells density in the outer 
cerebellar cortex layer at PN15, a phenotype widely rescued by the CD treatment. (A) 
A representative Hoechst-33258 stained sections of wt, Npc1nmf164 and Npc1nmf164 CD-treated mice 
are shown in figure. Higher magnification fields of EGL base or crown of lobules II and X on the right 
of low magnification fields show that the EGL of PN15 Npc1nmf164 mice is thinner than that of age-
matched wt mice. CD treatment makes the EGL of Npc1nmf164 mice comparable with that of wild type 
mice. Scale bar indicate 250 μm (panels) and 50 μm (insets). (B) Histogram represent GN densities 
(mean ± SEM of all sections examined; N = 4 mice/genotype; 3–4 sections/mouse) determined in 100 
μm2 regions of the crowns of wt, Npc1nmf164 and Npc1nmf164 CD-treated mice anterior (I-V) and posterior 
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(VI-X) lobules. Graphs show that CD treatment rescues the number of granule cells that can still be 
found in EGL of Npc1nmf164 mice at PN15. Asterisks indicate statistically significant differences 
(unpaired two-tailed Student’s t test, ** p < 0.001; *** p < 0.0001). 
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3.4.3. The reduced density of GNs in the EGL is due to defective 
proliferation of precursors 
 
The finding that Npc1nmf164 mice display a shorter lasting EGL compared to age 
matched wt suggested that the clock driving symmetric division of GN precursors could be 
dysregulated, leading these cells to prematurely exit from cell cycle.  
This possibility was investigated by determining the number of cells incorporating 
BrdU 20 hours after a single BrdU injection of PN13 or PN15 wt, Npc1nmf164 and Npc1nmf164 
CD-treated mice. This analysis showed that the number of BrdU-positive cells in both crowns 
and fissures of anterior cerebellar lobules was significantly reduced in Npc1nmf164.  
In posterior cerebellar lobules a reduction of BrdU-positive cells was only observed in 
fissures of PN15 Npc1nmf164 mice.  
CD treatment led Npc1nmf164 mice to display a number of BrdU-positive cells similar 
to that of wt mice (Figure 3A,B). 
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Figure 3. Npc1nmf164 mice display reduced number of proliferating granule neurons 
that is rescued by CD treatment. (A) A representative field showing BrdU-positive cells 
(red) of fissure between lobules II and III of PN13 wt, Npc1nmf164 and Npc1nmf164 CD-treated 
mice. Scale bar indicates 50 μm. (B) Histograms represent the number of BrdU-positive cells 
(mean ± SEM; 4 mice/genotype; 3–4 sections/mouse) determined in 100 μm2 regions 
corresponding to the bases and crowns of PN13 and PN15 wt, Npc1nmf164 and Npc1nmf164 
CD-treated mice anterior (I–V) and posterior (VI–X) lobules. The number of BrdU immune-
positive granule neurons is significantly reduced in cerebellum of Npc1nmf164 mice compared 
with age-matched wt
 
mice, a phenomenon more pronounced in the anterior than in posterior 
folia. Graphs show that in the CD-treated Npc1nmf164 mice the number of proliferating granule 
neurons is comparable to the number present in wild type.  Asterisks indicate statistically 
significant differences (unpaired two-tailed Student’s t test, ** p < 0.001; *** p < 0.0001). 
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3.4.4. GN precursor proliferation defect results in a disorganized 
cellular architecture of the EGL  
 
Since early postnatal development, the EGL splits into two layers, an outer layer 
(oEGL) containing mitotically-active p27Kip1-negative GNs progenitors and an inner layer 
(iEGL) containing p27Kip1-positive post-mitotic GNs that are differentiating and migrating 
toward their final destination in the IGL (Altman, 1972; Miyazawa et al., 2000).  
To gain insights on GNs development in the EGL of Npc1nmf164 mice, we performed 
an immunohistochemistry analysis for p27Kip1 detection on cerebella slices of wt, Npc1nmf164 
and Npc1nmf164 CD-treated mice at PN11. This analysis revealed that the stereotyped and 
ordered EGL architecture in the inner and outer sub-regions markedly differed between wt 
and Npc1nmf164 mice (Figure 4). Indeed, p27Kip1-immunopositive cells were scattered along 
the entire EGL and apparently represented the largest fraction of Npc1nmf164 mouse GNs, 
indicating that at PN11, the niche of mitotically active, p27Kip1-negative GNs (identifying the 
oEGL) is strongly reduced or even lost in Npc1nmf164 mice. CD treatment re-established the 
sharp boundary between the outer and inner EGLs (Figure 4).  
A scheme representing the feature of GN proliferation in wt, Npc1nmf164 and 
Npc1nmf164 CD-treated mouse EGLs, based on the findings so far described, is shown in 
Figure 5.  
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Figure 4. Cerebellar granule neurons of Npc1nmf164 mice exit the cell cycle earlier than 
those of wt mice. Cerebellar sections of PN11 wt, Npc1nmf164 and Npc1nmf164 CD-treated mice (3–4 
mice/group; 3–4 sections/mouse) were immunostained with anti-p27Kip1 antibodies (brown). Nuclei 
were stained with methyl green. A representative field of fissure between lobules II and III is shown. 
Note the presence of scattered p27Kip1-positive GNs along the entire EGL of Npc1nmf164. The CD 
treatment fully reestablished the p27Kip1 expression pattern in Npc1nmf164 mice. Scale bars indicate 50 
μm.  
 
 
 
 
 
Figure 5.  A model of defective GN proliferation in the Npc1nmf164 mice. 
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3.4.5. Npc1nmf164 mice display abnormal Bergmann glia morphogenesis 
and early astrocyte activation that are not rescued by the CD 
treatment   
 
During the first weeks of postnatal development, BG radial shafts span the entire 
ML, providing the scaffold for GN migration (Gregory et al., 2004) and directing the distal 
growth of the PC dendritic tree (Lordkipanidze et al., 2005).  
Further BG development favors PC dendritic arborization and synapse formation, leading to 
the complex reticular meshwork of the adult cerebellar cortex (Yamada and Watanabe, 
2002).  
In normal conditions, astrocyte play a key role in the formation, maintenance, 
function and pruning of synapses, as well as in regulating neurotransmitter uptake and 
maintaining the blood–brain barrier (Molofsky et al., 2012; Pekny et al., 2014).  
CNS injury or neurodegeneration results in astrocyte activation, or reactive gliosis, in which 
both astrocyte cell body and processes become hypertrophic and modify their gene 
expression pattern, upregulating the intermediate filament Glial Fibrillary Acidic Protein 
(GFAP) (Sofroniew, 2009). 
It has been shown that in Npc1-/- mice there is an increase of activated astrocyte 
number starting from 7-8 week of age (German et al., 2002). Maue and coll. (2012) found a 
similar phenotype also in Npc1nmf164 but this analysis was performed only at the terminal 
stages of the disease (PN120) and not during cerebellar development (Maue et al., 2012).  
To determine whether Npc1-deficiency affected BG morphology and caused the 
activation of astrocytes at early developmental stages, we assessed the expression and 
pattern of GFAP, by immunohistochemistry and Western blot analysis. While no significant 
difference was found between Npc1nmf164 and wt mice at PN11 (Figure 6C), BG of PN15 
Npc1nmf164 mice had radial shafts, which were enlarged and irregular in caliber and displayed 
hypertrophic astrocytes in the IGL (Figure 6A). The overall increase in size of BG and 
astrocytes of Npc1nmf164 mice was accompanied by an abnormal increase in GFAP 
expression, as quantified by Western blot analysis (Figure 6B).  
It is worth noting the presence of two GFAP protein bands having an apparent MW 
of 50 and 48 kDa, respectively, both more abundant in Npc1nmf164 mice compared to wt 
littermates (main effect of genotype: 48 kDa, t6 = 4.34, p = 0.005; 50 kDa, t6 = 3.44, 
p = 0.01).  
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The 48 kDa protein band is generated by calpain I proteolytic cleavage (Lee et al., 2000) 
and increases during neurodegenerative processes (Fujita et al., 1998). 
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Figure 6. Npc1nmf164 mice display an abnormal Bergmann glia morphogenesis and an 
early astrocytes activation. (A) Immunostaining with antibodies directed to GFAP (brown) shows 
that BG of PN15 Npc1nmf164 mice have radial shafts that are enlarged and irregular in caliber, as well 
as hypertrophic astrocytes within the IGL, compared to wt littermates. Representative fields of 
parasagittal sections of wt and Npc1nmf164 mouse cerebella are shown in the Figure; scale bars: 50 μm. 
Higher magnification fields are shown on the right; scale bars: 25 μm. ML: Molecular Layer; PCL: 
Purkinje Cell Layer; IGL: Internal Granular Layer. Western blot analysis of GFAP protein expression in 
cerebella of PN11 (B) and PN15 (C) wt and Npc1nmf164 mice. Histograms indicate the abundance 
(mean ± SEM) of each GFAP isoforms determined by densitometry of protein bands obtained in at 
least 3 independent experiments taking β-actin as internal reference. * p ≤ 0.01 
 
To evaluate the efficacy of CD treatment in rescuing this phenotype, we assessed 
the expression pattern of GFAP in PN15 wt and Npc1nmf164, either sham- or CD-treated 
mouse cerebella by immunohistochemistry and Western blot analysis. This analysis showed 
that CD treatment didn’t rescue defective BG morphology and astrocyte activation of 
Npc1nmf164 mice, as CD-treated wt mice display enlarged radial shaft and hypertrophic 
astrocytes similar to those of Npc1nmf164 (results of statistical analyses are shown in Table 
4) (Figure 7). 
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Figure 7. CD treatment does not rescue defective BG morphology and astrocyte 
activation. (A) Immunostaining with antibodies directed to GFAP (brown) of PN15 wt and Npc1nmf164, 
either sham- or CD-treated mouse cerebella. Note that CD-treated wt mice display enlarged radial 
shaft and hypertrophic astrocytes similar to those of Npc1nmf164. Representative fields of parasagittal 
sections are shown; scale bar indicate 50 μm. Higher magnification fields are shown on the right; scale 
bars: 25 μm. ML: Molecular Layer; PCL: Purkinje Cell Layer; IGL: Internal Granular Layer. (B) Western 
blot analysis of GFAP protein expression in cerebella of PN15 wt and Npc1nmf164 mice, either sham- or 
CD-treated. Histograms indicate the abundance (mean ± SEM) of each protein determined by 
densitometry of protein bands of at least 3 independent experiments taking β-actin as internal 
reference. * p ≤ 0.01, ** p < 0.001, *** p < 0.0001 
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3.4.6. Bergmann glia functions are defective in Npc1nmf164 mice  
 
BG is normally provided with a large amount of GLutamate ASpartate Transporter 
(GLAST), which is particularly abundant in the cell body and perisynaptic membranes, here 
preventing glutamate spillover between adjacent PCs (Takayasu et al., 2009).  
We determined GLAST expression by immunostaining and Western blot analyses 
at PN11 and PN15. Although no difference were found at PN11, we observed a significant 
GLAST reduction in Npc1nmf164 compared to wt littermates at PN15 (main effect of genotype: 
t6 = 4.27, p = 0.005) (Figure 8A,C).  
Such GLAST reduction was particularly evident around PC soma, which are normally 
enwrapped by lamellar processes arising from BG cell bodies (Palay and Chan-Palay, 1974; 
Caviness et al., 1995; Yamada and Watanabe, 2002) and in the distal BG radial shaft close 
to the pial surface.  
Because after the uptake into BG, glutamate is converted by the enzyme Glutamine 
synthetase into glutamine and recycled back to synapses for reconversion into active 
transmitter (Sofroniew and Vinters, 2010), we also determined Glutamine synthetase 
expression by immunostaining and Western blot analyses at PN11 and PN15.  
Consistently with our findings with GLAST expression, we found a significant Glutamine 
synthetase reduction in Npc1nmf164 compared to wt littermates at PN15 (main effect of 
genotype: t6 = 4.79, p = 0.003) but not at PN11 (Figure 8B,D).  
The decrease in Glutamine synthetase was stronger at the level of BG soma and milder 
along BG radial shafts.  
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Figure 8. Bergmann glia function appears to be defective in Npc1nmf164 mice. (A) 
Immunostaining with antibodies directed to GLAST (brown) shows that PN15 Npc1nmf164 mice display 
a reduced expression of GLAST at the level of BG processes in the outer part of molecular layer 
(arrowheads) and around Purkinje cell soma (arrows) compared to wt littermates. Representative fields 
of parasagittal sections of wt and Npc1nmf164 mouse cerebella are shown in the Figure 36a; scale bars: 
10 μm. Higher magnification fields are shown on the right; scale bars: 5 μm. (B) Immunostaining with 
antibodies directed to Glutamine synthetase (brown) shows that PN15 Npc1nmf164 mice display a 
reduced expression of Glutamine synthetase at the level of BG soma (arrowheads) and processes 
compared to wt littermates. Representative fields of parasagittal sections of wt and Npc1nmf164 mouse 
cerebella are shown in the Figure 36b; scale bars: 20 μm. Higher magnification fields are shown on 
the right; scale bars: 5 μm. ML: Molecular Layer; PCL: Purkinje Cell Layer. Western blot analyses of 
GLAST (C) and Glutamine synthetase (D) protein expression in cerebella of PN11 and PN15 wt and 
Npc1nmf164 mice. Histograms indicate GLAST (C) and Glutamine synthetase (D) abundance 
(mean ± SEM) determined by densitometry of protein bands obtained in at least 3 independent 
experiments taking the β-actin as internal reference. * p < 0.01 
 
CD treatment only rescued Glutamine syntethase deficiency (results of statistical 
analyses are shown in Table 4) (Figure 9). 
 
Figure 9. CD treatment partially rescue the defective Bergmann glia function of 
Npc1nmf164 mice. Western blot analysis of (A) GLAST and (B) Glutamine synthetase protein 
expression in cerebella of PN15 wt and Npc1nmf164 mice, either sham- or CD-treated. Histograms 
indicate the abundance (mean ± SEM) of each protein determined by densitometry of protein bands of 
at least 3 independent experiments taking β-actin as internal reference. * p ≤ 0.01, ** p < 0.001, *** 
p < 0.0001 
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3.4.7. The cerebellar cortex of PN15 wt and Npc1nmf164 mice displays 
similar densities of Bergmann glia, Purkinje cells and 
Basket/Stellate interneurons 
 
The prominent neuropathological sign of NP-C disease is the massive loss of PCs 
(Higashi et al., 1993; Ong et al., 2001). In Npc1nmf164 mice PC degeneration and loss begins 
at PN30 and becomes very pronounced at PN60 leading to cerebellar ataxia (Maue et al., 
2012).  
It was estimated that in rodent cerebellum there are ~8 BG cells per PC and that 
each PC receives over 100.000 inputs from inhibitory interneurons enwrapped by BG 
processes (Ito et al., 2008; Reichenbanch et al., 2010). The inhibitory input that PCs receive 
from Basket/stellate interneurons (BCs/SCs) is essential to provide the appropriate motor 
output (Wulff et al., 2009).  
Therefore, we decided to determine BG, PC and BC/SC densities in Npc1nmf164. The 
number of BG, PCs and BCs/SCs was determined by counting cell nuclei in randomly 
selected regions of 0.04 mm2 each in parasagittal cerebellar sections of PN15 wt and 
Npc1nmf164 mice stained with Hematoxylin/eosin Y (Figure 10; right panel) or processed for 
immunostaining with anti-parvalbumin antibody (Figure 10; left panel) to better identify 
GABAergic neurons/interneurons.  
The number and localization of GABAergic interneurons, PC and BG appeared similar in 
Npc1nmf164 and wt mice (see histograms in Figure 10).  
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Figure 10. The cerebellar cortex of PN15 wt and Npc1nmf164 mice displays similar 
densities of Bergmann glia, Purkinje cells and basket/stellate interneurons. 
Hematoxylin/eosin Y staining (right panel; asterisks: migrating GNs; arrows: basket/stellate 
interneurons; arrowheads: Bergmann glia) and immunostaining with anti-parvalbumin antibody (left 
panel); Scale bar: 50 μm. Histograms represent cell densities (mean ± SEM of all sections examined; 
N = 3 mice/genotype; 3–4 sections/mouse) determined in 0.04 mm2 regions randomly selected in each 
microscopic field of anterior (I-V) and posterior (VI-X) lobules of wt and Npc1nmf164 mouse cerebella, 
stained with Hematoxylin/eosin Y (right) or anti-parvalbumin antibody (left). Since any significant 
difference was found between counts of anterior and posterior lobules, values were averaged. 
Comparisons were performed by unpaired two-tailed Student’s t test. 
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3.4.8.  Purkinje cells of Npc1nmf164 mice display a reduced number of 
glutamatergic and GABAergic inputs which is rescued by the CD 
treatment  
 
PCs display distinct anatomical and functional compartments, which receive at least 
two excitatory and two inhibitory inputs on different proximal and distal sub-compartments 
of cerebellar cortex (Palay and Chan-Palay, 1974) respectively, dividing the molecular layer 
into outer and inner parts.  
In fact, thin distal PC dendrite branchlets receive glutamatergic inputs from parallel fibers 
and GABAergic inputs from SCs (Ango et al., 2004), whereas the thick proximal PC dendritic 
shafts receive synapses mostly from GABAergic BCs and glutamatergic climbing fibers 
(Ichikawa et al., 2002).  
We studied glutamatergic and GABAergic inputs to PCs by immunostaining 
histological sections of PN15 Npc1nmf164 and wt cerebella with antibodies directed to 
vesicular glutamate transporter subtype 2 (VGluT2, labeling glutamatergic terminals) and 
glutamic acid decarboxylase 65 (GAD65, labeling GABAergic terminals).  
Compared to wt littermates, the ML of Npc1nmf164 mouse cerebella displayed a 
reduced number of VGluT2-positive puncta, which was particularly pronounced at the level 
of outer part of ML (main effect of genotype: t6 = 3.87, p = 0.008), whereas differences at the 
level of inner molecular layer didn’t reach statistical significance (main effect of genotype: 
t6 = 2.55, p = 0.04) (Figure 11A).  
As expected, VGluT2 immunostaining was also detected at the level of glomeruli, where 
glutamatergic afferent mossy fibers synapse with GN dendrites, with similar expression 
patterns in wt and Npc1nmf164 mice.  
Finally, Western blot analysis revealed a significant reduction of VGluT2 protein levels in the 
cerebellum of PN15 Npc1nmf164 mice (main effect of genotype: t6 = 4.75, p = 0.003) (Figure 
11B)  
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Figure 11. Purkinje cells of Npc1nmf164 mice display a reduced number of glutamatergic 
inputs. (A) Immunostaining with antibodies directed to VGluT2 (brown) shows that PN15 Npc1nmf164 
mice display a reduced expression of VGluT2 in the outer part of molecular layer compared to wt 
littermates. Representative fields of parasagittal sections of lobule II of wt and Npc1nmf164 mouse 
cerebella are shown. Upper panels: arrows indicate VGluT2-positive synapses of internal granule layer 
glomeruli; scale bars: 20 μm. Bottom panels: higher magnifications of selected areas. Arrowheads 
indicate typical VGluT2 positive puncta; scale bars: 5 μm. Histograms indicate VGluT2-positive puncta 
densities in the outer and inner molecular layers (mean ± SEM). (B) Western blot analysis of VGluT2 
protein expression in cerebella of PN15 wt and Npc1nmf164 mice. Histograms indicate VGluT2 
abundance (mean ± SEM) determined by densitometry of protein bands obtained in at least 3 
independent experiments taking the β-actin as internal reference. * p < 0.01 
 
Although the number and localization of GABAergic interneurons along the ML 
appeared similar in Npc1nmf164 and wt mice (see Figure 10), the analysis of GAD65 
expression patterns showed that GABAergic inputs were significantly reduced in Npc1nmf164 
cerebella.  
To investigate this issue, we arbitrarily divided the ML into outer and inner and 
determined the density of GAD65-positive puncta in both upper and lower ML and PCL, 
observing a significant reduction of puncta in molecular and PC layers of Npc1nmf164 vs wt 
mice (main effect of genotype: outer ML: t6 = 3.64, p = 0.01; lower ML: t6 = 3.44, p = 0.01; 
PCL: t6 = 3.58, p = 0.01) (Figure 12A).  
Reduced GAD65 expression was also confirmed by Western blot analysis (main effect of 
genotype: t6 = 3.71, p = 0.01) (Figure 40b).  
No difference in the expression level of GAD65 were found at PN11 between wt and 
Npc1nmf164 mice (Figure 12B).   
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Figure 12. Purkinje cells of Npc1nmf164 mice display a reduced number of GABAergic 
inputs. (A) Immunostaining with antibodies directed to GAD65 (brown) shows a reduced density of 
GAD65-positive puncta (arrowheads) around Purkinje cell soma and throughout the entire molecular 
layer of PN15 Npc1nmf164 mice compared to wt littermates. Representative fields of parasagittal 
sections of lobule II wt and Npc1nmf164 mice cerebella are shown in the Figure 40a; scale bars: 10 μm. 
Higher magnifications are shown in bottom panel insets; Arrowheads indicate typical GAD65-positive 
puncta; scale bars: 10 μm. Histograms indicate the density of GAD65-positive puncta in outer and 
inner molecular layers and Purkinje cell layer. (B) Western blot analysis of GAD65 protein expression 
in cerebella of PN11 and PN15 wt and Npc1nmf164 mice. Histograms indicate GAD65 abundance 
(mean ± SEM) determined by densitometry of protein bands obtained in at least 3 independent 
experiments taking the β-actin as internal reference. * p = 0.01 
 
 
To evaluate the efficacy of CD treatment in rescuing this phenotype, we assessed 
the expression pattern of GAD65 and VGluT2 in PN15 wt and Npc1nmf164, either sham- or 
CD-treated mouse cerebella by Western blot analysis. This analysis showed that CD 
treatment fully rescue these deficits (Figure 13A,B) (results of statistical analyses are shown 
in Table 4). The efficacy of CD in restoring the normal VGluT2 expression pattern were also 
confirmed by immunohistochemistry. This analysis revealed that Npc1nmf164 display an 
abundance and distribution of VgluT2-puncta similar to that of wt mice (Figure 13C,D). 
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Figure 13. CD treatment fully rescued the reduced number of 
GABAergic/glutamatergic inputs. Western blot analyses of GAD65 (A) and VGluT2 (B) protein 
expression in cerebella of PN15 wt and Npc1nmf164 mice either sham- or CD-treated. Histograms 
indicate the abundance (mean ± SEM) of each protein determined by densitometry of protein bands of 
at least 3 independent experiments taking β-actin as internal reference. * p ≤ 0.01, ** p < 0.001, *** 
p < 0.0001 (C) Immunostaining with antibodies directed to VGluT2 (brown) of PN15 wt and Npc1nmf164, 
either sham- or CD-treated mouse cerebella. Representative fields of parasagittal sections are shown 
in the figure. Upper panels, arrows indicate VGluT2-positive synapses of internal granule layer 
glomeruli; scale bars: 20 μm. Bottom panels, higher magnifications of selected areas. Arrowheads 
indicate VGluT2 positive puncta; scale bars: 5 μm. (D) Histograms indicate VGluT2-positive puncta 
densities in the outer and inner molecular layers (mean ± SEM of all sections examined; N = 4 
mice/genotype/treatment; 3–4 sections/mouse) of wt and Npc1nmf164 mice, either sham- or CD-treated. 
Asterisks indicate statistically significant differences (two-way ANOVA, * p < 0.01). 
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3.4.9.   Npc1nmf164 mice display defective myelin maturation 
 
It was recently shown that the selective ablation of Npc1 expression in 
oligodendrocytes results in defective myelin formation in the forebrain and corpus callosum 
of PN16 mice (Yu and Lieberman, 2013) indicating that these cells need exogenous 
cholesterol uptake at least during early postnatal life. This finding is in agreement with 
previous observations showing the expression of low-/very low-density lipoprotein receptors 
by oligodendrocytes (Zhao et al., 2007) and the dependence on glia-derived cholesterol of 
Npc1-deficient brains (Borbon et al., 2012; Zhang et al., 2008).  
Moreover, dysmyelination and myelin loss were previously reported in prefrontal 
cortex, corpus callosum and hippocampus of Npc1−/− mice (Takikita et al., 2004) and found 
to be associated with defective genetic control of oligodendrocyte differentiation (Yan et al., 
2011).  
To investigate whether/how Npc1-deficiency also affected myelin formation during 
cerebellum development, we determined the expression of myelin basic protein (MBP), a 
well-established marker of mature myelin (Baumann et al., 2001) in PN11 and PN15 
cerebella of Npc1nmf164 and wt mice.  
As shown by Western blot analysis (Figure 14A) the level of MBP isoforms was significantly 
reduced with respect to wt at either PN11 (main effect of genotype: 17.2 kDa: t6 = 4.21, 
p = 0.006; 18.5 kDa: t6 = 4.38, p = 0.005; 21.5 kDa: t6 = 4.03, p = 0.007) and PN15 (main 
effect of genotype: 17.2 kDa: t6 = 4.76, p = 0.003; 18.5 kDa: t6 = 3.51, p = 0.01; 21.5 kDa: 
t6 = 21.86, p = 0.000001).  
Various MBP isoforms are generated by alternative splicing and exert specific 
functions in different intracellular compartments. Namely, the 17.2 and 21.5 kDa isoforms 
are highly expressed in the cell body and nucleus of developing oligodendrocytes, playing a 
regulatory role in the genetic program of oligodendrocyte differentiation (Pedraza et al., 
1997). In contrast, the 18.5 kDa isoform localizes at the plasma membrane and actively 
participates in membrane compaction typical of mature myelin (Harauz and Boggs, 2013). 
Immunohistochemistry of PN15 cerebellar sections fully confirmed the impairment of myelin 
formation in Npc1nmf164 mice, showing a significant reduction of MBP immunostaining at the 
level of PC axons and white matter (Figure 14B).  
To further characterize this defect, similar analyses were also performed on cerebral cortex 
and corpus callosum, i.e. brain areas in which individual oligodendrocytes are more easily 
detected (Figure 14C).  
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Based on these analyses, the dysmyelination of Npc1nmf164 mice appeared to be associated 
with poor oligodendrocyte differentiation, as indicated by the reduced length of the processes 
that typically radiate from oligodendrocyte soma. Accordingly, the MBP immunostaining of 
cerebral cortex and corpus callosum was strongly reduced, in agreement with previous 
observations (Takikita et al., 2004).  
CD administration to Npc1nmf164 mice fully rescued the decrease of MBP, restoring protein 
levels similar to those of sham wt mouse cerebella (results of statistical analyses are shown 
in Table 4) (Figure 14D).   
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Figure 14. Oligodendrocyte maturation is impaired in Npc1nmf164 mice. (A) Western blot 
analysis of MBP protein expression in cerebella of PN11 and PN15 wt and Npc1nmf164 mice. Histograms 
indicate the abundance (mean ± SEM) of each isoform determined by densitometry of protein bands 
obtained in at least 3 independent experiments taking β-actin as internal reference. * p ≤ 0.01, *** 
p < 0.0001. (B) Immunostaining with antibodies directed to MBP (brown) shows that PN15 Npc1nmf164 
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mouse cerebella display a reduction of MBP expression at the level of PC axons and white matter 
compared to wt littermates. Representative fields of parasagittal sections of lobule III of PN15 wt and 
Npc1nmf164 mouse cerebella are shown in the Figure; scale bars: 100 μm. (C) Immunostaining with 
antibodies directed to MBP (brown) showing that PN15 Npc1nmf164 mice display a poorer 
oligodendrocyte differentiation as indicated by the reduced length of MBP-positive processes that 
typically radiate from oligodendrocyte soma (arrowheads), compared to wt littermates. Representative 
fields of parasagittal sections of PN15 wt and Npc1nmf164 mouse cerebral cortex (Cx) and splenium of 
corpus callosum (scc) are shown in the Figure; scale bars: 100 μm. Higher magnifications are shown 
in panel C (bottom); scale bars: 20 μm. (D) Western blot analysis of MBP protein expression in 
cerebella of PN15 wt and Npc1nmf164 mice either sham- or CD-treated. Histograms indicate the 
abundance (mean ± SEM) of each protein determined by densitometry of protein bands of at least 3 
independent experiments taking β-actin as internal reference. * p ≤ 0.01, ** p < 0.001, *** p < 0.0001 
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3.4.10.   Npc1nmf164 mice display normal levels of activated microglia but 
a reduced microglia-mediated phagocytosis  
 
Microglia plays a crucial role in the regulation of brain development and homeostasis 
secreting several signaling molecules, such as cytokines, neurotransmitters (e.g. glutamate) 
and trophic factors (e.g. BDNF) that promote neurogenesis, neuronal growth/survival, 
oligodendrogenesis, synaptic activity and functional plasticity (Tay et al., 2016).  
During development, activated microglia phagocytes apoptotic neurons, as well as 
pathogens to promote tissue repair/remodeling (Minghetti and Levi, 1998; Goldmann and 
Prinz, 2013) and mediates synaptic pruning to increase the efficiency of neuronal 
transmissions (Marin-Teva et al., 2004; Peri and Nùsslein-Volhard, 2008; Paolicelli et al., 
2011; Swinnen et al., 2013).  
We studied the microglia activation assessing by Western blot analysis the 
expression levels of CD11b at PN15, finding no significant differences between wt and 
Npc1nmf164 littermates. The treatment with CD didn’t vary the expression level of this protein 
in both genotypes (results of statistical analysis are shown in Table 4) (Figure 15A).  
We also evaluated the ability of activated microglia to phagocyte cell debris 
determining CD68 expression by Western blot analysis at PN15, observing a significant 
CD68 reduction in Npc1nmf164 compared to wt littermates. Treatment with CD fully rescued 
this phenotype (results of statistical analysis are shown in Table 4) (Figure 15B).  
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Figure 15. Npc1nmf164 mice display a reduced microglia-mediated phagocytosis. 
Western blot analyses of CD11b (A) and CD68 (B) protein expression in cerebella of PN15 wt and 
Npc1nmf164 mice either untreated or CD-treated. Histograms indicate the abundance (mean ± SEM) of 
each protein determined by densitometry of protein bands of at least 3 independent experiments taking 
β-actin as internal reference. * p ≤ 0.01, ** p < 0.001, *** p < 0.0001 
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3.4.11.   Npc1nmf164 mice display an abnormal BNDF signaling pathway  
 
Among signaling pathways controlling cerebellar development, BDNF, by binding 
the lipid raft-associated TrkB receptor, acts as a chemiokinetic factor to induce GNs 
migration and as chemiodinamic factor to guide GNs along BGs fibers (Borghesani et al., 
2002). Also, BDNF is required for the development of dendritic spines and arborization of 
PCs and axonal growth of GNs, to modulate the dendritic morphology of BCs/SCs and to 
regulate the cholesterol metabolism for synapses formation (Morrison and Mason, 1998 
Suzuki et al., 2007; Mertz et al., 2000).  
Mature-BDNF is synthesized from pro-BDNF, which in turn can act as a signaling molecule 
by binding P75NTR receptors (Barker, 2009).  
However, during neurodevelopment pro-BDNF mediates opposite effects compared to 
BNDF, by promoting apoptosis and negatively regulating neurite growth, dendritic spine 
formation and GNs migration (Lu, 2005; Khoshimizu et al., 2009).  
In addition, there is an intermediate isoform, truncated-BDNF, but at present its functional 
role remains unknown (Carlino et al., 2013).  
It has been shown that Shh signaling promotes the expression of BDNF through a 
post-transcriptional mechanism (Bond et al., 2013), suggesting that both pro-BDNF and 
BDNF signaling pathway could be altered in Npc1nmf164 mice.  
To investigate this issue, we determined the expression levels of pro-BDNF, 
truncated-BDNF, mature-BDNF, TrkB and P75NTR by Western blot analyses in cerebella of 
PN11 mice, observing a significant reduction of all proteins examined in Npc1nmf164 
compared to wt littermates (results of statistical analyses are shown in Table 4) (Figure 16).  
CD treatment re-stored expression levels similar to those of wt for mature-BDNF, 
truncated-BDNF, mature-BDNF and P75NTR but not for TrkB (Figure 16).  
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Figure 16. Npc1nmf164 mice display an abnormal BNDF signaling pathway.  Western blot 
analyses of pro-BDNF, truncated BDNF, mature BDNF (A) TrkB (B) and P75NTR (C) protein expression 
in cerebella of PN11 wt and Npc1nmf164 mice either untreated or CD-treated. Histograms indicate the 
abundance (mean ± SEM) of each protein determined by densitometry of protein bands of at least 3 
independent experiments taking β-actin as internal reference. * p ≤ 0.01, ** p < 0.001, *** p < 0.0001 
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3.4.12.  Npc1nmf164 mice show a delay in the acquisition of complex 
motor skills requiring fine motor coordination and balance  
 
Because sensorimotor reflexes and motor skills normally appear with a definite 
timing during the first 3 weeks after birth, they represent a useful tool to assess early 
postnatal neural development (de Souza et al., 2004).  
We therefore evaluated the acquisition of several developmental milestones in the 
physical and sensorimotor development of Npc1nmf164 mice from PN3 until weaning (PN21).  
Body weight, fur appearance, incisor eruption and eye opening were recorded as indexes of 
physical growth and development, observing no difference between Npc1nmf164 and wt 
littermates (Figure 17A). All pups similarly increased their body weight in the interval PN3-
PN21 (main effect of genotype: F1,18 = 0.80, p = 0.78; main effect of age: F18,324 = 364.14, 
p < 0.00001; interaction between genotype and age: F18,324 = 0.47, p = 0.97), and showed 
dorsal and ventral fur appearance after PN5 (main effect of genotype: Z = −1.30, p = 0.47), 
incisor eruption after PN7 (main effect of genotype: Z = 0.32, p = 0.80), and eye opening after 
PN14 (main effect of genotype: Z = −1.58, p = 0.14).  
To analyze the locomotor development we determined the appearance of the 
dominant locomotor categories pivoting (turning with circular motions), crawling (moving 
forward/pushing backward the body) and quadrupedal locomotion (showing fluent and swift 
forward movements), observing no difference between Npc1nmf164 and wt littermates (Figure 
17B, Table 5). Namely, pups showed pivoting from PN3 to PN9, crawling at PN10-11 and 
quadrupedal locomotion since PN12.  
We also determined the development of swimming abilities and observed no effect 
of genotype: all pups floated with asynchronous limb movements at PN4, swam in circles at 
PN5, swam in a straight line at PN12 and displayed the adult swimming pattern (paddling 
only the hindlimbs) after PN14 (Figure 17C,D, Table 5).  
We then recorded the appearance of reflexes as surface righting reflex, negative 
geotaxis and cliff avoidance, which involve vestibular, tactile and proprioceptive systems 
(Altman and Sudarshan, 1975).  
Negative geotaxis and cliff avoidance are more representative of sensory ability, 
whereas the surface righting reflex is more representative of motor ability (Heyser, 2004). 
Npc1nmf164 mice displayed a timing of reflex appearance that matched that of wt littermates 
(Figure 17E), exhibiting similar appearance of surface righting reflex (main effect of 
genotype: Z = −1.70, p = 0.10) and negative geotaxis since PN4 (main effect of genotype: 
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Z = 0.38, p = 0.74), as well as cliff avoidance since PN7 (main effect of genotype: Z = 0.20, 
p = 0.85). 
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Figure 17. Npc1nmf164 pups show a delay in the acquisition of complex motor skills 
requiring fine motor coordination and balance. (A) Line graph indicates body weight values 
of experimental group mice of increasing age. Histograms indicate the day of onset of physical 
development landmarks. (B-D) Histograms indicate the fraction of: pups engaged in pivoting, crawling 
or quadrupedal locomotion (B); pups floating, swimming in circles or in a straight line (C); pups paddling 
with only forelimbs, four limbs or only hindlimbs (D) in the PN3-PN15 time interval. (E-F) Histograms 
indicate the day of onset of sensorimotor reflexes (E) and complex motor skills (F). Note that Npc1-
deficiency delays the acquisition of complex motor behaviors requiring fine motor coordination and 
balance, whereas it does not influence physical and sensorimotor development. (A, E, F) Data are 
expressed as mean ± SEM. (B-D) Data are expressed as percentages of animals displaying the 
behavior. * p ≤ 0.01 
 
Ageb 
Quadrupedal 
locomotion 
Swimming performance 
direction limb usage 
PN3 Z = 1.00; p = 0.74 Z = 0.00; p = 1.00 Z = 0.00; p = 1.00 
PN4 Z = -1.00; p = 0.74 Z = 0.00; p = 1.00 Z = 0.00; p = 1.00 
PN5 Z = 1.00; p = 0.74 Z = 1.90; p = 0.14 Z = 0.89; p = 0.48 
PN6 Z = -1.00; p = 0.74 Z = 0.00; p = 1.00 Z = 1.09; p = 0.48 
PN7 Z = -0.61; p = 0.74 Z = 0.00; p = 1.00 Z = 1.00; p = 0.74 
PN8 Z = 0.97; p = 0.53 Z = 0.00; p = 1.00 Z = 0.00; p = 1.00 
PN9 Z = -0.59; p = 0.63 Z = 0.00; p = 1.00 Z = 0.00; p = 1.00 
PN10 Z = 0.00; p = 1.00 Z = 0.00; p = 1.00 Z = -1.00; p = 0.74 
PN11 Z = -1.09; p = 0.48 Z = -1.09; p = 0.48 Z = -1.00; p = 0.74 
PN12 Z = 1.37; p = 0.28 Z = 0.89; p = 0.48 Z = 0.00; p = 1.03 
PN13 Z = -1.13; p = 0.44 Z = 1.83; p = 0.28 Z = 0.89; p = 0.48 
PN14 Z = -1.45; p = 0.48 Z = 0.00; p = 1.00 Z = 2.18; p = 0.14 
PN15 Z = 0.00; p = 1.00 Z = 0.00; p = 1.00 Z = 1.00; p = 0.74 
 
Table 5. Statistical analysis outputs of quadrupedal locomotion and swimming 
performance development in Npc1nmf164 and wt littermatesa 
a Experimental groups were compared at increasing postnatal days by Mann-Whitney U test  
 b PN: postnatal day 
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In the mouse, complex motor abilities requiring fine limb coordination, 
balance and muscle strength are normally acquired by the end of the second 
postnatal week.  
Three tasks (ascending a ladder, crossing a narrow bridge and suspension 
on a wire) allowed us to differentiate the contribution of motor coordination and 
balance from that of grip and muscle strength. Npc1nmf164 pups acquired these 
abilities with a significant delay compared to wt littermates (Figure 17F).  
Indeed, whereas wt pups crossed the narrow bridge in its entire length and hanged 
on the wire with four limbs after PN14, Npc1nmf164 mice crossed the bridge only at 
PN17 (main effect of genotype: Z = −2.54, p = 0.01) and developed the four-limb 
hanging ability at PN18 (main effect of genotype: Z = −2.98, p = 0.004). In contrast, 
grip ability and muscle strength developed similarly in Npc1nmf164 and wt littermates, 
as shown by their similar ability to ascend the ladder after PN15 (main effect of 
genotype: Z = 0.27, p = 0.80) and to hang on the wire for a longer time with 
increasing age (main effect of genotype: F1,18 = 1.09, p = 0.31; main effect of age: 
F10,180 = 3.23, p = 0.0008; interaction between genotype and age: F10,180 = 0.20, 
p = 0.99).              
The possibility of evaluating the efficacy of CD to rescue the developmental 
delay in motor skills acquisition of Npc1nmf164 and wt littermates was hampered by 
the hyperactivity of mouse pups elicited by the injection per se. Both CD-treated and 
sham group pups, regardless of genotype resisted our attempts to perform motor 
behavior assessments. 
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3.4.13.   Motor deficits of Npc1nmf164 mice become more severe in the 
adulthood 
 
To fully characterize motor phenotype in adults, PN30, PN60 and PN90 Npc1nmf164 
and wt littermates were subjected to a battery of tests including Vertical screen, Balance 
beam, and Coat hanger. 
The Vertical screen test (similar to the ascending on a ladder) investigates the 
climbing response that requires good grip and muscle strength (Figure 18A). In this test 
Npc1nmf164 mice reached the upper edge of the screen more slowly than wt littermates, even 
if both genotypes turned upwards with similar time (turning upward: main effect of genotype: 
F1,18 = 0.12, p = 0.73; main effect of age: F2,36 = 1.91, p = 0.16; interaction between 
genotype and age: F2,36 = 1.52, P = 0.23); (climbing to the upper edge: main effect of 
genotype: F1,18 = 11.31, p = 0.004; main effect of age: F2,36 = 0.59, p = 0.57; interaction 
between genotype and age: F2,36 = 2.63, p = 0.09). 
The Balance beam test (similar to crossing a narrow bridge) measures fine motor 
coordination and balance (Figure 18B). When placed on an elevated round beam, 
Npc1nmf164 mice crossed significantly fewer beam sections than wt mice did and significantly 
fewer sections as days went by (main effect of genotype: F1,18 = 34.92, p = 0.00001; main 
effect of age: F2,36 = 5.08, p = 0.01; interaction between genotype and age: F2,36 = 4.09, 
p = 0.03). Moreover, Npc1nmf164 mice did not differ from wt until PN90 in terms of retention 
time (main effect of genotype: F1,18 = 54.28, p < 0.00001; main effect of age: F2,36 = 6.48, 
p = 0.004; interaction between genotype and age: F2,36 = 6.01, p = 0.006). 
The Coat hanger test (similar to suspending on a wire) further characterizes motor 
coordination by providing an “agility score” (Figure 18C). Npc1nmf164 mice obtained scores 
lower than those of wt mice when suspended on the coat hanger. In fact, while wt mice 
rapidly escaped to the bar end, Npc1nmf164 mice did not progress to the end of the bar 
although they were able to grasp the bar with four limbs (main effect of genotype: 
F1,18 = 18.81, p = 0.0004; main effect of age: F2,36 = 3.80, p = 0.03; interaction between 
genotype and age: F2,36 = 2.30, p = 0.11). 
The possibility that body weight influenced motor behavior was routinely checked before all 
behavioral evaluations (Figure 18D). Body weight of Npc1nmf164 and wt mice did not differ at 
PN30 and PN60, while it significantly decreased in PN90 Npc1nmf164 mice, as previously 
described (Maue et al., 2012) (main effect of genotype: F1,18 = 13.35, p = 0.002; main effect 
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of age: F2,36 = 125.40, p < 0.00001; interaction between genotype and age: F2,36 = 22.26, 
p < 0.00001). 
 
 
Figure 18. Npc1nmf164 adult mice display motor deficits after PN30. (A-D) 
Histograms indicate: latency values to turn upward and climb to the upper edge in the Vertical 
screen test (A); number of sections crossed and retention time values in the Balance beam 
test (B); rating score values in the Coat hanger test (C); body weight values (D) of 
experimental group mice of increasing age. All data are expressed as mean ± SEM. * p < 0.01, 
** p < 0.001, *** p < 0.0001 
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Table 4. Statistical analysis outputs on WB assays of wt and Npc1nmf164 littermates 
either sham- or CD-treated. 
a  differences were analyzed by two-way ANOVAs 
b wt and Npc1nmf164 littermates received subcutaneous injections of plain PBS or CD at PN4 and PN7. 
 
 
 
 
 Genotypea Treatmentb Genotype x treatment 
GFAP 
50 kDa F(1,12)=29.35, p=0.0001 F(1,12)=52.17, p<0.0001 F(1,12)=0.70, p=0.42 
48 kDa F(1,12)=199.21, p<0.0001 F(1,12)=152.93, p<0.0001 F(1,12)=8.78, p=0.01 
GLAST 60 kDa F(1,12)=22.77, p=0.0005 F(1,12)=95.83, p<0.0001 F(1,12)=9.63, p=0.01 
Glutamine 
Synthetase 
42 kDa F(1,12)=12.85, p=0.004 F(1,12)=12.51, p=0.004 F(1,12)=11.48, p=0.005 
VGluT2   65 kDa F(1,12)=0.83, p=0.38 F(1,12)=5.47, p=0.04 F(1,12)=26.21, p=0.0003 
GAD65 65 kDa F(1,12)=13.53, p=0.003 F(1,12)=22.02, p=0.0005 F(1,12)=21.89, p=0.0005 
 21.5 kDa F(1,12)=0.14, p=0.71 F(1,12)=3.37, p=0.09 F(1,12)=74.51, p<0.0001 
MBP 18.5 kDa F(1,12)=0.04, p=0.84 F(1,12)=5.60, p=0.04 F(1,12)=24.13, p=0.0004 
 17.2 kDa F(1,12)=1.55, p=0.24 F(1,12)=47.36, p<0.0001 F(1,12)=92.86, p<0.0001 
CD11b 170 kDa F(1, 20)=2.47, p=0.01 F(1, 20)=3.54, p=0.01 F(1,12)=5.69, p=0.01 
CD68 37 kDa F(1, 20)=17.78, p<0.01 F(1, 20)=19.89, p<0.01 F(1, 20)=21.86, p<0.01 
pro-BDNF 32 kDa F(1, 20)=129.04, p<0.0001 F(1, 20)=0,73, p=0.40 F(1, 20)=393.79, p<0.0001 
truncated-
BDNF 
28 kDa F(1, 20)=103.62, p<0.0001 F(1, 20)=0.02 , p=0.006 F(1, 20)=533.19, p<0.0001 
mature-
BDNF 
15 kDa F(1, 20)=90.850, p<0.0001 F(1, 20)=13.81, p=0.001 F(1, 20)=84.11, p<0.0001 
TrkB 92 kDa F(1, 20)=87.85, , p<0.0001 F(1, 20)=83.85, , p<0.0001 F(1, 20)=12.85, p=0.001 
p75NTR 75 kDa F(1, 20)=17.038, p=0.002 F(1, 20)=84.55, p<0.0001 F(1, 20)=150.76, p<0.0001 
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Discussion and conclusions 
 
 
This study disclosed several developmental anomalies that impinge on the 
functionality of Purkinje cells (PCs), suggesting the possibility that the selective vulnerability 
of these cells represents the final outcome of defective differentiation of glial and neuronal 
cells forming the ordered pattern of cell-to-cell interaction and synaptic connectivity of 
cerebellar cortex (Llinas et al., 2004).  
According to evidence recently obtained by our group, showing that both Sonic 
Hedgehog (Shh) availability and reception are severely impaired by Npc1-deficiency (Nusca 
et al., 2014; Canterini et al., manuscript in preparation) it is likely that abnormal cerebellar 
morphogenesis is a consequence of an impairment of Shh signaling. This possibility is 
strengthened by the finding that the C-terminus of proteolytically-generated active Shh 
fragment is modified by the covalent attachment of a cholesterol moiety (Repetto et al., 1990; 
Lanoue et al., 1997; Dehart et al., 1997). Moreover, cholesterol availability influences the 
function of lipid rafts that play a key role in signal transduction (Crane and Tamm, 2004).    
 
 Effect of altered Shh signaling on cerebellar morphogenesis  
 
Our findings indicate that altered Shh signaling causes a poorer morphological 
differentiation of Bergmann glia (BG) as indicated by thicker radial shafts and a less 
elaborate reticular pattern of lateral processes. This could compromise the cerebellar 
function since the BG processes organize the compartmentalization pattern of synaptic 
inputs that reach PCs (Palay and Chan-Palay, 1974) playing a prominent role in the 
differential guidance and targeting of basket and stellate cell axons (Ango et al., 2004) and 
regulate cerebellar synaptic activity (Buffo and Rossi, 2013) by almost completely 
enwrapping the synapses that parallel and climbing fibers establish with PCs (Yamada and 
Watanabe, 2002; Palay and Chan-Palay, 1974). In particular, the glutamate transporter 
GLAST finely regulates PC firing at BG perisynaptic processes by preventing glutamate 
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spillover between adjacent PCs (Takayasu et al., 2009) and maintaining the one-to-one 
functional relationship between climbing fibers and PCs that is crucial for cerebellar control 
of motor function (Watase et al., 1998; Chen et al., 1995; Offermanns et al., 1997). Because 
the glutamate recovered by GLAST is metabolized to glutamine by Glutamine synthetase 
(Bak et al., 2006) the reduced expression of GLAST and Glutamine synthetase 
in Npc1nmf164 mice is in line with the proposal that GLAST is a limiting factor in glutamate 
synthesis (Martinez et al., 2014).  
Also, GFAP plays a key role in astrocyte-neuron interactions, by modulating the trafficking 
and function of astrocytic and neuronal glutamate transporters, as well as glutamine 
production (Middeldorp and Hol, 2011). All together these findings suggest that the abnormal 
morphological differentiation of BG affects the functional specialization of their processes, 
as also indicated by the reduced expression of GLAST and Glutamine synthetase. In 
addition to BG, a decrease of GLAST and Glutamine synthetase expression is likely to occur 
in astrocytes, the functional impairment of which is indicated by astrocytosis displayed 
by Npc1nmf164 cerebella.  
Npc1 is also abundant in the recycling endosomes of presynaptic terminals. In fact, 
Npc1-deficiency results in morphological, biochemical and functional modification of both 
excitatory and inhibitory presynaptic terminals and synaptic vesicle turnover (Karten et al., 
2006). This may explain the reduction of both excitatory and inhibitory inputs received by 
PCs, as indicated by the significant reduction of VGluT2 and GAD65 puncta. This imbalance 
of synaptic inputs associated with Npc1-deficiency is in agreement with previous findings 
showing a decrease of synaptic inputs to PCs in co-cultures of Npc1-deficient neurons and 
glial cells (Buard and Pfrieger, 2014).  
The lower number of granule neurons (GNs) that are generated in the cerebellum 
of Npc1nmf164 mice likely contributes to the reduction in glutamatergic inputs, as indicated by 
our finding that VGluT2 puncta reduction is prominent in the outer molecular layer, which is 
mostly made of GN axons. On the other hand, the GN reduction may also impinge on the 
full differentiation of basket/stellate interneurons, which, among other intrinsic genetic 
programs and extracellular cues, depends on connectivity with GN axons (Rakic, 1972; 
Cameron et al., 2009). Along the same line, the lower number of GNs may also be 
responsible for the abnormal differentiation of BG processes in Npc1nmf164 mice, because 
the glutamate released by parallel fibers modulates the degree of BG perisynaptic 
envelopment acting through calcium-permeable AMPA receptors (Buffo and Rossi, 2013).  
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Defective oligodendrocyte maturation likely underlines the overall reduction in MBP 
we have observed in Npc1nmf164 cerebellum, in line with previous studies showing 
dysmyelination in both NPC patients and Npc1−/− mice (Takikita et al., 2004; Walterfang et 
al., 2010). Moreover, the decreased MBP expression not only affected the 18.5 kDa (specific 
to mature oligodendrocytes), but also the 17.5 kDa and 21.5 kDa isoforms (specific to 
developing oligodendrocytes), indicating that oligodendrocyte differentiation per se is also 
impaired in Npc1-deficient mice. Although Npc1 deletion in neurons triggers the block of 
oligodendrocyte maturation and thus leads to a subsequent failure of myelin formation (Yu 
and Lieberman, 2013) the exogenous cholesterol uptake by oligodendrocytes coupled to 
Npc1-mediated intracellular trafficking is also relevant for the formation of myelin sheaths 
(Zhao et al., 2007; Yan et al., 2011).  
 
Microglia involvement  
  
It is worth noting that in Npc1-/- mice astrocytosis is consistently accompanied by 
microglia activation (Maue et al., 2012; German et al., 2002; Baudry et al., 2003) and the 
down regulation of GLAST has been found to correlate with the release of inflammatory 
cytokines by activated microglia (Tilleux and Hermans, 2008). Interestingly, we have not 
found significant differences in the expression levels of CD11b, a well-established marker of 
microglia activation (Perego et al., 2011), whereas we have found reduced expression levels 
of the lysosomal/endosomal-associated membrane glycoprotein CD68 which represents a 
useful marker of microglia-mediated active phagocytosis (Perego et al., 2011). This 
observation suggests that in Npc1nmf164 mice activated microglia fails to destroy pathogens 
and apoptotic neurons as well as to phagocyte synaptic elements during synaptic pruning, 
which in turn may cause inflammation and defective synapse formation and maturation. 
However, further investigations are needed to explore these issues. 
 
Effect of altered BDNF signaling on cerebellar morphogenesis  
 
Among signaling pathways controlling cerebellar development, Brain-Derived 
Neurotrophic Factor (BDNF), by binding the lipid raft-associated tropomyosin receptor 
kinase B (TrkB) exerts a crucial for proper proliferation and differentiation of various neuronal 
and glial cell, likely influencing the overall pattern of synaptic connectivity of the cerebellar 
cortex (Saab et al., 2003; Borghesani et al., 2002; Merz et al., 2000; Kokubo et al., 2009). 
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Also, BDNF elicits neuronal de novo synthesis of cholesterol stimulating the transcription of 
several enzymes involved in the cholesterol biosynthetic pathway (Suzuki et al., 2007). The 
BDNF-dependent cholesterol biosynthesis plays a critical role for the development of 
synapses and lipid rafts (Suzuki et al., 2007). The BDNF reduced availability may also alter 
the composition of lipid rafts observed in both NPC1-patient and mice (Kuech et al., 2014; 
Vainio et al., 2005), which in turn may explain the reduced TrkB expression that we have 
observed. Because Shh signaling promotes the expression of BDNF through a post-
transcriptional mechanism (Bond et al., 2013), BDNF-deficiency may also depend on the 
reduced availability of Shh. According to this hypothesis we have observed a downregulation 
of the expression levels of BDNF precursor protein, namely pro-BDNF, and its high-affinity 
receptor p75NTR. Further investigations are needed to quantify the pro-BDNF transcripts and 
highlight if the reduction of BDNF protein occurs in neuronal or glial, as it is synthetized and 
released by PCs, GNs, BG, intraparenchymal astrocytes, oligodendrocytes and microglia 
(Marini et al., 1998; Jean et al., 2008; Poblete-Naredo et al., 2011; Coull et al., 2005). Our 
findings indicate that the expression of BDNF and TrkB is downregulated in in the cerebellum 
of Npc1nmf164 mice, as early as at PN11. These findings pinpoint BDNF dysregulation, among 
others molecular mechanisms, as a possible candidate responsible for abnormal cerebellum 
morphogenesis, opening novel perspectives for NP-C1 disease therapies. 
 
Motor behavior anomalies 
  
These overall disturbances of cerebellar morphogenesis cause in Npc1nmf164 mice a 
delay in the acquisition of complex motor skills, that require fine motor coordination and 
balance, in spite of a normal physical and postural development. The presence of a 
developmental delay instead of a more severe deficit of these abilities is likely explained by 
the greater plasticity of developing cerebellum and/or the availability of cholesterol of 
neuronal origin before the full shift to astrocyte-derived cholesterol, which compensates the 
deficit of Npc1 function. 
The normal appearance of sensorimotor reflexes and locomotion development 
of Npc1nmf164 pups within the first two postnatal weeks indicate that vestibular, tactile, and 
proprioceptive systems; descending motor pathways; and brain stem-spinal networks 
(Altman and Sudarshan, 1975; Clarac et al., 2004) are not apparently affected by Npc1-
deficiency. Conversely, the domain of complex motor abilities is damaged by Npc1-
deficiency because they are also prematurely lost in the adulthood. In fact, motor 
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coordination and balance are more severely impaired than grip capacity and muscle strength 
as early as at PN30 and these motor defects thereafter translate to severe ataxia, because 
of the massive PC degeneration (Maue et al., 2012; Võikar et al., 2002).   
The acquisition of complex motor abilities depends on proper sequencing and 
coordination of motor outputs. These are prominent properties of cerebellar circuitry 
(Dehorter et al., 2012) consisting of several functional modules that allow the real-time 
control of movements and the long-term changes underling motor learning, by finely 
regulated signal generation and flow that ultimately converge on PCs. The inhibitory activity 
of PCs is dynamically orchestrated at the level of both dendritic shafts and cell body by a 
number of excitatory and inhibitory neurons, while PCs in turn modulate the excitability of 
deep cerebellar nuclei. Therefore, an altered pattern of synaptic inputs to PCs may affect 
the timing of their firing and finally result in behavior abnormalities. For example, it was 
recently demonstrated that an altered GN development results in impaired motor 
coordination (Ceccarelli et al., 2015; Prestori et al., 2008).  
Similar features were also reported as a consequence of a defective development of BG 
processes (Müller Smith et al., 2012; Watase et al., 1998) likely because correct BG 
development is crucial for cerebellar cytoarchitecture and function processes (Müller Smith 
et al., 2012). Conversely, a precocious BG and PC maturation is associated with an earlier 
acquisition of motor abilities in young and improved motor learning and coordination in adult 
mice (Marazziti et al., 2013).  
In light of these findings, it is possible that the developmental delay in the acquisition 
of complex motor skills we have observed in Npc1nmf164 pups results from a derangement of 
synaptic inputs to PCs. 
 
Efficacy of CD treatment  
 
Present findings also demonstrate that early postnatal CD treatment effectively re-
wires developmental trajectories, by partly rescuing the defective cerebellar morphogenesis 
and thus explaining the well-established beneficial effect a single CD administration to 
PN7 Npc1−/− mice has in rescuing lysosomal cholesterol accumulation and slowing down the 
appearance of ataxic symptoms (Camargo et al., 2001; Raminez et al., 2010; Vite et al., 
2015; Davidson et al., 2009; Liu et al., 2008). In fact, this treatment is particularly timely 
because cerebellar morphogenesis maximizes the need for cholesterol, making the 
exogenous LDL-uptaken cholesterol a rate-limiting factor for neurons (Fiorenza et al., 2013; 
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Zhang and Liu, 2015). Noteworthy, CD administration didn’t rescue either GFAP hyper- or 
GLAST hypo-expression of Npc1nmf164 mice, although it fully rescued Glutamine synthetase 
levels in these mice. Because Glutamine synthetase is mainly expressed by astrocytes, this 
observation rules out the possibility that astrocytes are not influenced by CD, making this 
issue worthy of further investigation, also in light of the ability of CD administration to 
influence GFAP and GLAST expression of wt mice.  
 
Conclusions 
 
In conclusion, we have demonstrated that the downregulation in both synthesis and 
release of Shh by PCs causes an abnormal GNs proliferation, as well as a number of glial 
cell differentiation anomalies, derangement of synaptic input to PCs and a down-regulation 
of BDNF expression that in turn, may correlate with the delay of complex motor skills 
acquisition of Npc1nmf164 mice. In this contest, microglia fail to perform active phagocytosis. 
We believe that these findings are relevant because: i) delineate a novel perspective 
to explain the selective Purkinje cell vulnerability in NPC1 mouse models and patients; and, 
ii) emphasize the need of early diagnosis to secure the best treatment efficacy in patients. 
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